See Full Prescribing Information For Complete Boxed Warning

1
HIGHLIGHTS OF PRESCRIBING INFORMATION • Safety of the coadministration of doses above 18 mg olanzapine with 75
mg fluoxetine has not been evaluated (2.5, 2.6)
These highlights do not include all the information needed to use
PROZAC safely and effectively. See full prescribing information for ---------------------- DOSAGE FORMS AND STRENGTHS ---------------------
PROZAC. • Pulvules: 10 mg, 20 mg, 40 mg (3)
PROZAC (fluoxetine hydrochloride) Pulvules for oral use • Weekly capsules: 90 mg (3)
PROZAC (fluoxetine hydrochloride) delayed-release capsules for oral use -------------------------------CONTRAINDICATIONS------------------------------
• Do not use with an MAOI or within 14 days of discontinuing an MAOI
due to risk of drug interaction. At least 5 weeks should be allowed after
Initial U.S. Approval: 1987 stopping PROZAC before treatment with an MAOI (4, 7.1)
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS • Do not use with pimozide due to risk of drug interaction or QTc
prolongation (4, 7.9)
See full prescribing information for complete boxed warning. • Do not use with thioridazine due to QTc interval prolongation or
Increased risk of suicidal thinking and behavior in children, adolescents, potential for elevated thioridazine plasma levels. Do not use thioridazine
and young adults taking antidepressants for Major Depressive within 5 weeks of discontinuing PROZAC (4, 7.9)
Disorder (MDD) and other psychiatric disorders (5.1). • When using PROZAC and olanzapine in combination, also refer to the
When using PROZAC and olanzapine in combination, also refer to Boxed Contraindications section of the package insert for Symbyax (4)
Warning section of the package insert for Symbyax.
------------------------ WARNINGS AND PRECAUTIONS -----------------------
--------------------------- RECENT MAJOR CHANGES -------------------------- • Clinical Worsening and Suicide Risk: Monitor for clinical worsening
and suicidal thinking and behavior (5.1)
------------------------ INDICATIONS AND USAGE --------------------------- • Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like
PROZAC® is a selective serotonin reuptake inhibitor indicated for: Reactions: Have been reported with PROZAC. Discontinue PROZAC
• Acute and maintenance treatment of Major Depressive Disorder (MDD) and initiate supportive treatment (5.2)
in adult and pediatric patients aged 8 to 18 years (1.1) • Allergic Reactions and Rash: Discontinue upon appearance of rash or
• Acute and maintenance treatment of Obsessive Compulsive allergic phenomena (5.3)
Disorder (OCD) in adult and pediatric patients aged 7 to 17 years (1.2) • Activation of Mania/Hypomania: Screen for Bipolar Disorder and
• Acute and maintenance treatment of Bulimia Nervosa in adult patients monitor for mania/hypomania (5.4)
(1.3) • Seizures: Use cautiously in patients with a history of seizures or with
• Acute treatment of Panic Disorder, with or without agoraphobia, in adult conditions that potentially lower the seizure threshold (5.5)
patients (1.4) • Altered Appetite and Weight: Significant weight loss has occurred (5.6)
PROZAC and olanzapine in combination for: • Abnormal Bleeding: May increase the risk of bleeding. Use with
• Acute treatment of Depressive Episodes Associated with Bipolar I NSAIDs, aspirin, warfarin, or drugs that affect coagulation may
Disorder in adults (1.5) potentiate the risk of gastrointestinal or other bleeding (5.7)
• Acute treatment of Treatment Resistant Depression in adults (Major • Hyponatremia: Has been reported with PROZAC in association with
Depressive Disorder in adult patients who do not respond to 2 separate syndrome of inappropriate antidiuretic hormone (SIADH) (5.8)
trials of different antidepressants of adequate dose and duration in the • Anxiety and Insomnia: May occur (5.9)
current episode) (1.6) • Potential for Cognitive and Motor Impairment: Has potential to impair
----------------------- DOSAGE AND ADMINISTRATION ---------------------- judgment, thinking, and motor skills. Use caution when operating
machinery (5.11)
• Long Half-Life: Changes in dose will not be fully reflected in plasma for
Indication Adult Pediatric several weeks (5.12)
MDD (2.1) 20 mg/day in am (initial dose) 10 to 20 mg/day • PROZAC and Olanzapine in Combination: When using PROZAC and
(initial dose) olanzapine in combination, also refer to the Warnings and Precautions
section of the package insert for Symbyax (5.14)
OCD (2.2) 20 mg/day in am (initial dose) 10 mg/day (initial
dose) ------------------------------- ADVERSE REACTIONS ------------------------------
Bulimia Nervosa 60 mg/day in am - Most common adverse reactions (≥5% and at least twice that for placebo)
(2.3) associated with:
Panic Disorder (2.4) 10 mg/day (initial dose) - Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia, and
Panic Disorder: abnormal dreams, abnormal ejaculation, anorexia, anxiety,
Depressive Episodes Oral in combination with - asthenia, diarrhea, dry mouth, dyspepsia, flu syndrome, impotence, insomnia,
Associated with olanzapine: 5 mg of oral libido decreased, nausea, nervousness, pharyngitis, rash, sinusitis,
Bipolar I Disorder olanzapine and 20 mg of somnolence, sweating, tremor, vasodilatation, and yawn (6.1)
(2.5) fluoxetine once daily (initial
dose) PROZAC and olanzapine in combination – Also refer to the Adverse
Reactions section of the package insert for Symbyax (6)
Treatment Resistant Oral in combination with -
Depression (2.6) olanzapine: 5 mg of oral To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and
olanzapine and 20 mg of Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088
fluoxetine once daily (initial or www.fda.gov/medwatch
dose) ------------------------------- DRUG INTERACTIONS ------------------------------
• Consider tapering the dose of fluoxetine for pregnant women during the • Monoamine Oxidase Inhibitors (MAOI): PROZAC is contraindicated for
third trimester (2.7) use with MAOI’s, or within 14 days of discontinuing an MAOI due to
• A lower or less frequent dosage should be used in patients with hepatic risk of drug interaction. At least 5 weeks should be allowed after
impairment, the elderly, and for patients with concurrent disease or on stopping PROZAC before starting treatment with an MAOI (4, 7.1)
multiple concomitant medications (2.7) • Pimozide: PROZAC is contraindicated for use with pimozide due to risk
• Dosing with PROZAC Weekly capsules - initiate 7 days after the last of drug interaction or QTc prolongation (4, 7.9)
daily dose of PROZAC 20 mg (2.1) • Thioridazine: PROZAC is contraindicated for use with thioridazine due
PROZAC and olanzapine in combination: to QTc interval prolongation or potential for elevated thioridazine plasma
• Dosage adjustments, if indicated, should be made with the individual levels. Do not use thioridazine within 5 weeks of discontinuing
components according to efficacy and tolerability (2.5, 2.6) PROZAC (4, 7.9)
• Fluoxetine monotherapy is not indicated for the treatment of Depressive • Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of
Episodes associated with Bipolar I Disorder or treatment resistant CYP2D6 enzyme pathway (7.9)
depression (2.5, 2.6)
Reference ID: 2927282

2
• Tricyclic Antidepressants (TCAs): Monitor TCA levels during • Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma
coadministration with PROZAC or when PROZAC has been recently concentrations (7.8, 7.9)
discontinued (7.9) • Olanzapine: When used in combination with PROZAC, also refer to the
• CNS Acting Drugs: Caution should be used when taken in combination Drug Interactions section of the package insert for Symbyax (7.9)
with other centrally acting drugs (7.2)
• Benzodiazepines: Diazepam – increased t ½ , alprazolam - further ------------------------USE IN SPECIFIC POPULATIONS-----------------------
psychomotor performance decrement due to increased levels (7.9) • Pregnancy: PROZAC should be used during pregnancy only if the
• Antipsycotics: Potential for elevation of haloperidol and clozapine levels potential benefit justifies the potential risks to the fetus (8.1)
(7.9) • Nursing Mothers: Breast feeding is not recommended (8.3)
• Anticonvulsants: Potential for elevated phenytoin and carbamazepine • Pediatric Use: Safety and effectiveness of PROZAC and olanzapine in
levels and clinical anticonvulsant toxicity (7.9) combination have not been established in patients less than 18 years of
• Serotonergic Drugs: Potential for Serotonin Syndrome (5.2, 7.3) age (8.4)
• Triptans: There have been rare postmarketing reports of Serotonin • Hepatic Impairment: Lower or less frequent dosing may be appropriate
Syndrome with use of an SSRI and a triptan (5.2, 7.4) in patients with cirrhosis (8.6)
• Tryptophan: Concomitant use with tryptophan is not recommended (5.2, See 17 for PATIENT COUNSELING INFORMATION and FDA-
7.5) approved Medication Guide
• Drugs that Interfere with Hemostasis (e.g. NSAIDs, Aspirin, Warfarin): Revised: [00/0000]
May potentiate the risk of bleeding (7.6)
FULL PRESCRIBING INFORMATION: CONTENTS* 7.6 Drugs that Interfere with Hemostasis (e.g., NSAIDS, Aspirin,
Warfarin)
WARNING — SUICIDALITY AND ANTIDEPRESSANT DRUGS 7.7 Electroconvulsive Therapy (ECT)
1 INDICATIONS AND USAGE 7.8 Potential for Other Drugs to affect PROZAC
1.1 Major Depressive Disorder 7.9 Potential for PROZAC to affect Other Drugs
1.2 Obsessive Compulsive Disorder 8 USE IN SPECIFIC POPULATIONS
1.3 Bulimia Nervosa 8.1 Pregnancy
1.4 P
anic Disorder 8.2 Labor and Delivery
1.5 PROZAC and Olanzapine in Combination: Depressive Episodes 8.3 Nursing Mothers
Associated with Bipolar I Disorder 8.4 P
ediatric Use
1.6 PROZAC and Olanzapine in Combination: Treatment Resistant 8.5 Geriatric Use
Depression 8.6 Hepatic Impairment
2 DOSAGE AND ADMINISTRATION 9 DRUG ABUSE AND DEPENDENCE
2.1 Major Depressive Disorder 9.3 D
ependence
2.2 Obsessive Compulsive Disorder
2.3 Bulimia Nervosa 10 OVERDOSAGE
2.4 P
anic Disorder 10.1 Human Experience
2.5 PROZAC and Olanzapine in Combination: Depressive Episodes 10.2 Animal Experience
Associated with Bipolar I Disorder 10.3 Management of Overdose
2.6 PROZAC and Olanzapine in Combination: Treatment Resistant 11 DESCRIPTION
Depression
12 CLINICAL PHARMACOLOGY
2.7 Dosing in Specific Populations 12.1 Mechanism of Action
2.8 Discontinuation of Treatment 12.2 Pharmacodynamics
3 DOSAGE FORMS AND STRENGTHS 12.3 Pharmacokinetics
4 CONTRAINDICATIONS 12.4 S
pecific Populations
5 W
ARNINGS AND PRECAUTIONS 13 NONCLINICAL TOXICOLOGY
5.1 Clinical Worsening and Suicide Risk 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
5.2 Serotonin Syndrome or Neuroleptic Malignant Syndrome
13.2 Animal Toxicology and/or Pharmacology
(NMS)-like Reactions 14 CLINICAL STUDIES
5.3 Allergic Reactions and Rash 14.1 Major Depressive Disorder

5.4 Screening Patients for Bipolar Disorder and Monitoring for 14.2 Obsessive Compulsive Disorder
Mania/Hypomania 14.3 Bulimia Nervosa
5.5 Seizures 14.4 Panic Disorder

5.6 Altered Appetite and Weight 16 HOW SUPPLIED/STORAGE AND HANDLING
5.7 Abnormal Bleeding 16.1 How Supplied
5.8 Hyponatremia 16.2 Storage and Handling
5.9 Anxiety and Insomnia
5.10 Use in Patients with Concomitant Illness 17 PATIENT COUNSELING INFORMATION
5.11 Potential for Cognitive and Motor Impairment 17.1 General Information
5.12 Long Elimination Half-Life 17.2 Clinical Worsening and Suicide Risk
5.13 Discontinuation of Treatment 17.3 Serotonin Syndrome or Neuroleptic Malignant Syndrome
5.14 PROZAC and Olanzapine in Combination (NMS)-like Reactions
17.4 Allergic Reactions and Rash
6 A
DVERSE REACTIONS 17.5 Abnormal Bleeding
6.1 Clinical Trials Experience 17.6 Hyponatremia
6.2 Other Reactions 17.7 Potential for Cognitive and Motor Impairment
6.3 Postmarketing Experience 17.8 Use of Concomitant Medications
7 DRUG INTERACTIONS 17.9 Discontinuation of Treatment
7.1 Monoamine Oxidase Inhibitors (MAOI) 17.10 Use in Specific Populations
7.2 CNS Acting Drugs *Sections or subsections omitted from the full prescribing information are not
7.3 Serotonergic Drugs listed
7.4 T
riptans
7.5 Tryptophan

3
FULL PRESCRIBING INFORMATION
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children,
adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders.
Anyone considering the use of PROZAC or any other antidepressant in a child, adolescent, or young adult must balance this
risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants
compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in
adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the
risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed
closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the
need for close observation and communication with the prescriber. PROZAC is approved for use in pediatric patients with
MDD and Obsessive Compulsive Disorder (OCD) [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)].
When using PROZAC and olanzapine in combination, also refer to Boxed Warning section of the package insert for
Symbyax.
1 INDICATIONS AND USAGE

1.1 Major Depressive Disorder
PROZAC® is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in
pediatric patients aged 8 to 18 years [see Clinical Studies (14.1)].
The usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods, should periodically be re
evaluated [see Dosage and Administration (2.1)].
PROZAC is indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in
pediatric patients aged 7 to 17 years with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2)].
The effectiveness of PROZAC in long-term use, i.e., for more than 13 weeks, has not been systematically evaluated in
placebo-controlled trials. Therefore, the physician who elects to use PROZAC for extended periods, should periodically re-evaluate
the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.2)].
1.3 Bulimia Nervosa
PROZAC is indicated for the acute and maintenance treatment of binge-eating and vomiting behaviors in adult patients with
moderate to severe Bulimia Nervosa [see Clinical Studies (14.3)].
The physician who elects to use PROZAC for extended periods should periodically re-evaluate the long-term usefulness of the
drug for the individual patient [see Dosage and Administration (2.3)].
1.4 Panic Disorder
PROZAC is indicated for the acute treatment of Panic Disorder, with or without agoraphobia, in adult patients [see Clinical
Studies (14.4)].
The effectiveness of PROZAC in long-term use, i.e., for more than 12 weeks, has not been established in placebo-controlled
trials. Therefore, the physician who elects to use PROZAC for extended periods, should periodically re-evaluate the long-term
usefulness of the drug for the individual patient [see Dosage and Administration (2.4)].
1.5 PROZAC and Olanzapine in Combination: Depressive Episodes Associated with Bipolar I Disorder
When using PROZAC and olanzapine in combination, also refer to the Clinical Studies section of the package insert for
Symbyax®.
PROZAC and olanzapine in combination is indicated for the acute treatment of depressive episodes associated with Bipolar I
Disorder in adult patients.
PROZAC monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder.
1.6 PROZAC and Olanzapine in Combination: Treatment Resistant Depression
Symbyax.
PROZAC and olanzapine in combination is indicated for the acute treatment of treatment resistant depression (Major
Depressive Disorder in adult patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and
duration in the current episode).
PROZAC monotherapy is not indicated for the treatment of treatment resistant depression.
2 DOSAGE AND ADMINISTRATION
Initial Treatment

4
Adult — In controlled trials used to support the efficacy of fluoxetine, patients were administered morning doses ranging from
20 to 80 mg/day. Studies comparing fluoxetine 20, 40, and 60 mg/day to placebo indicate that 20 mg/day is sufficient to obtain a
satisfactory response in Major Depressive Disorder in most cases. Consequently, a dose of 20 mg/day, administered in the morning, is
recommended as the initial dose.
A dose increase may be considered after several weeks if insufficient clinical improvement is observed. Doses above
20 mg/day may be administered on a once-a-day (morning) or BID schedule (i.e., morning and noon) and should not exceed a
maximum dose of 80 mg/day.
Pediatric (children and adolescents) — In the short-term (8 to 9 week) controlled clinical trials of fluoxetine supporting its
effectiveness in the treatment of Major Depressive Disorder, patients were administered fluoxetine doses of 10 to 20 mg/day
[see Clinical Studies (14.1)]. Treatment should be initiated with a dose of 10 or 20 mg/day. After 1 week at 10 mg/day, the dose
should be increased to 20 mg/day.
However, due to higher plasma levels in lower weight children, the starting and target dose in this group may be 10 mg/day. A
dose increase to 20 mg/day may be considered after several weeks if insufficient clinical improvement is observed.
All patients — As with other drugs effective in the treatment of Major Depressive Disorder, the full effect may be delayed
until 4 weeks of treatment or longer.
Maintenance/Continuation/Extended Treatment — It is generally agreed that acute episodes of Major Depressive Disorder
require several months or longer of sustained pharmacologic therapy. Whether the dose needed to induce remission is identical to the
dose needed to maintain and/or sustain euthymia is unknown.
Daily Dosing — Systematic evaluation of PROZAC in adult patients has shown that its efficacy in Major Depressive Disorder
is maintained for periods of up to 38 weeks following 12 weeks of open-label acute treatment (50 weeks total) at a dose of 20 mg/day
[see Clinical Studies (14.1)].
Weekly Dosing — Systematic evaluation of PROZAC® Weekly™ in adult patients has shown that its efficacy in Major
Depressive Disorder is maintained for periods of up to 25 weeks with once-weekly dosing following 13 weeks of open-label treatment
with PROZAC 20 mg once daily. However, therapeutic equivalence of PROZAC Weekly given on a once-weekly basis with
PROZAC 20 mg given daily for delaying time to relapse has not been established [see Clinical Studies (14.1)].
Weekly dosing with PROZAC Weekly capsules is recommended to be initiated 7 days after the last daily dose of PROZAC
20 mg [see Clinical Pharmacology (12.3)].
If satisfactory response is not maintained with PROZAC Weekly, consider reestablishing a daily dosing regimen [see Clinical
Studies (14.1)].
Switching Patients to a Tricyclic Antidepressant (TCA) — Dosage of a TCA may need to be reduced, and plasma TCA
concentrations may need to be monitored temporarily when fluoxetine is coadministered or has been recently discontinued [see Drug
Interactions (7.9)].
Switching Patients to or from a Monoamine Oxidase Inhibitor (MAOI) — At least 14 days should elapse between
discontinuation of an MAOI and initiation of therapy with PROZAC. In addition, at least 5 weeks, perhaps longer, should be allowed
after stopping PROZAC before starting an MAOI [see Contraindications (4) and Drug Interactions (7.1)].
Initial Treatment
Adult — In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of OCD, patients were
administered fixed daily doses of 20, 40, or 60 mg of fluoxetine or placebo [see Clinical Studies (14.2)]. In one of these studies, no
dose-response relationship for effectiveness was demonstrated. Consequently, a dose of 20 mg/day, administered in the morning, is
recommended as the initial dose. Since there was a suggestion of a possible dose-response relationship for effectiveness in the second
study, a dose increase may be considered after several weeks if insufficient clinical improvement is observed. The full therapeutic
effect may be delayed until 5 weeks of treatment or longer.
Doses above 20 mg/day may be administered on a once daily (i.e., morning) or BID schedule (i.e., morning and noon). A dose
range of 20 to 60 mg/day is recommended; however, doses of up to 80 mg/day have been well tolerated in open studies of OCD. The
maximum fluoxetine dose should not exceed 80 mg/day.
Pediatric (children and adolescents) — In the controlled clinical trial of fluoxetine supporting its effectiveness in the
treatment of OCD, patients were administered fluoxetine doses in the range of 10 to 60 mg/day [see Clinical Studies (14.2)].
In adolescents and higher weight children, treatment should be initiated with a dose of 10 mg/day. After 2 weeks, the dose
should be increased to 20 mg/day. Additional dose increases may be considered after several more weeks if insufficient clinical
improvement is observed. A dose range of 20 to 60 mg/day is recommended.
In lower weight children, treatment should be initiated with a dose of 10 mg/day. Additional dose increases may be considered
after several more weeks if insufficient clinical improvement is observed. A dose range of 20 to 30 mg/day is recommended.
Experience with daily doses greater than 20 mg is very minimal, and there is no experience with doses greater than 60 mg.
Maintenance/Continuation Treatment — While there are no systematic studies that answer the question of how long to
continue PROZAC, OCD is a chronic condition and it is reasonable to consider continuation for a responding patient. Although the
efficacy of PROZAC after 13 weeks has not been documented in controlled trials, adult patients have been continued in therapy under

5
double-blind conditions for up to an additional 6 months without loss of benefit. However, dosage adjustments should be made to
maintain the patient on the lowest effective dosage, and patients should be periodically reassessed to determine the need for treatment.
2.3 Bulimia Nervosa
Initial Treatment — In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of Bulimia
Nervosa, patients were administered fixed daily fluoxetine doses of 20 or 60 mg, or placebo [see Clinical Studies (14.3)]. Only the 60
mg dose was statistically significantly superior to placebo in reducing the frequency of binge-eating and vomiting. Consequently, the
recommended dose is 60 mg/day, administered in the morning. For some patients it may be advisable to titrate up to this target dose
over several days. Fluoxetine doses above 60 mg/day have not been systematically studied in patients with bulimia.
Maintenance/Continuation Treatment — Systematic evaluation of continuing PROZAC 60 mg/day for periods of up to
52 weeks in patients with bulimia who have responded while taking PROZAC 60 mg/day during an 8-week acute treatment phase has
demonstrated a benefit of such maintenance treatment [see Clinical Studies (14.3)]. Nevertheless, patients should be periodically
reassessed to determine the need for maintenance treatment.
2.4 Panic Disorder
Initial Treatment — In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of Panic
Disorder, patients were administered fluoxetine doses in the range of 10 to 60 mg/day [see Clinical Studies (14.4)]. Treatment should
be initiated with a dose of 10 mg/day. After one week, the dose should be increased to 20 mg/day. The most frequently administered
dose in the 2 flexible-dose clinical trials was 20 mg/day.
A dose increase may be considered after several weeks if no clinical improvement is observed. Fluoxetine doses above
60 mg/day have not been systematically evaluated in patients with Panic Disorder.
Maintenance/Continuation Treatment — While there are no systematic studies that answer the question of how long to
continue PROZAC, panic disorder is a chronic condition and it is reasonable to consider continuation for a responding patient.
Nevertheless, patients should be periodically reassessed to determine the need for continued treatment.
2.5 PROZAC and Olanzapine in Combination: Depressive Episodes Associated with Bipolar I Disorder
Symbyax.
Fluoxetine should be administered in combination with oral olanzapine once daily in the evening, without regard to meals,
generally beginning with 5 mg of oral olanzapine and 20 mg of fluoxetine. Dosage adjustments, if indicated, can be made according to
efficacy and tolerability within dose ranges of fluoxetine 20 to 50 mg and oral olanzapine 5 to 12.5 mg. Antidepressant efficacy was
demonstrated with olanzapine and fluoxetine in combination with a dose range of olanzapine 6 to 12 mg and fluoxetine 25 to 50 mg.
Safety and efficacy of fluoxetine in combination with olanzapine was determined in clinical trials supporting approval of
Symbyax (fixed-dose combination of olanzapine and fluoxetine). Symbyax is dosed between 3 mg/25 mg (olanzapine/fluoxetine) per
day and 12 mg/50 mg (olanzapine/fluoxetine) per day. The following table demonstrates the appropriate individual component doses
of PROZAC and olanzapine versus Symbyax. Dosage adjustments, if indicated, should be made with the individual components
according to efficacy and tolerability.
Table 1: Approximate Dose Correspondence Between Symbyax1 and the Combination of PROZAC and Olanzapine
For Use in Combination
Symbyax Olanzapine PROZAC
(mg/day) (mg/day) (mg/day)
3 mg olanzapine/25 mg fluoxetine 2.5 20
6 mg olanzapine/25 mg fluoxetine 5 20
12 mg olanzapine/25 mg fluoxetine 10+2.5 20
6 mg olanzapine/50 mg fluoxetine 5 40+10
12 mg olanzapine/50 mg fluoxetine 10+2.5 40+10
1
Symbyax (olanzapine/fluoxetine HCL) is a fixed-dose combination of PROZAC and olanzapine.
While there is no body of evidence to answer the question of how long a patient treated with PROZAC and olanzapine in
combination should remain on it, it is generally accepted that Bipolar I Disorder, including the depressive episodes associated with
Bipolar I Disorder, is a chronic illness requiring chronic treatment. The physician should periodically re-examine the need for
continued pharmacotherapy.
Safety of coadministration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical studies.
PROZAC monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder.
2.6 PROZAC and Olanzapine in Combination: Treatment Resistant Depression
Symbyax.
Fluoxetine should be administered in combination with oral olanzapine once daily in the evening, without regard to meals,
generally beginning with 5 mg of oral olanzapine and 20 mg of fluoxetine. Dosage adjustments, if indicated, can be made according to

6
efficacy and tolerability within dose ranges of fluoxetine 20 to 50 mg and oral olanzapine 5 to 20 mg. Antidepressant efficacy was
demonstrated with olanzapine and fluoxetine in combination with a dose range of olanzapine 6 to 18 mg and fluoxetine 25 to 50 mg.
Safety and efficacy of fluoxetine in combination with olanzapine was determined in clinical trials supporting approval of
Symbyax (fixed dose combination of olanzapine and fluoxetine). Symbyax is dosed between 3 mg/25 mg (olanzapine/fluoxetine) per
day and 12 mg/50 mg (olanzapine/fluoxetine) per day. Table 1 demonstrates the appropriate individual component doses of PROZAC
and olanzapine versus Symbyax. Dosage adjustments, if indicated, should be made with the individual components according to
efficacy and tolerability.
While there is no body of evidence to answer the question of how long a patient treated with PROZAC and olanzapine in
combination should remain on it, it is generally accepted that treatment resistant depression (Major Depressive Disorder in adult
patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode) is a
chronic illness requiring chronic treatment. The physician should periodically re-examine the need for continued pharmacotherapy.
Safety of coadministration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical studies.
PROZAC monotherapy is not indicated for the treatment of treatment resistant depression (Major Depressive Disorder in
patients who do not respond to 2 antidepressants of adequate dose and duration in the current episode).
2.7 Dosing in Specific Populations
Treatment of Pregnant Women during the Third Trimester — When treating pregnant women with PROZAC during the third
trimester, the physician should carefully consider the potential risks and potential benefits of treatment. Neonates exposed to SNRIs or
SSRIs late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube
feeding. The physician may consider tapering PROZAC in the third trimester [see Use in Specific Populations (8.1)].
Geriatric — A lower or less frequent dosage should be considered for the elderly [see Use in Specific Populations (8.5)]
Hepatic Impairment — As with many other medications, a lower or less frequent dosage should be used in patients with
hepatic impairment [see Clinical Pharmacology (12.4) and Use in Specific Populations (8.6)].
Concomitant Illness — Patients with concurrent disease or on multiple concomitant medications may require dosage
adjustments [see Clinical Pharmacology (12.4) and Warnings and Precautions (5.10)].
PROZAC and Olanzapine in Combination — The starting dose of oral olanzapine 2.5 to 5 mg with fluoxetine 20 mg should
be used for patients with a predisposition to hypotensive reactions, patients with hepatic impairment, or patients who exhibit a
combination of factors that may slow the metabolism of olanzapine or fluoxetine in combination (female gender, geriatric age, non
smoking status), or those patients who may be pharmacodynamically sensitive to olanzapine. Dosing modifications may be necessary
in patients who exhibit a combination of factors that may slow metabolism. When indicated, dose escalation should be performed with
caution in these patients. PROZAC and olanzapine in combination have not been systematically studied in patients over 65 years of
age or in patients less than 18 years of age [see Warnings and Precautions (5.14) and Drug Interactions (7.9)].
2.8 Discontinuation of Treatment
Symptoms associated with discontinuation of fluoxetine, SNRIs, and SSRIs, have been reported [see Warnings and
Precautions (5.13)].
3 DOSAGE FORMS AND STRENGTHS
• 10 mg Pulvule is an opaque green cap and opaque green body, imprinted with DISTA 3104 on the cap and Prozac 10 mg
on the body
• 20 mg Pulvule is an opaque green cap and opaque yellow body, imprinted with DISTA 3105 on the cap and Prozac 20 mg
on the body
• 40 mg Pulvule is an opaque green cap and opaque orange body, imprinted with DISTA 3107 on the cap and Prozac 40 mg
on the body
• 90 mg Prozac Weekly™ Capsule is an opaque green cap and clear body containing discretely visible white pellets
through the clear body of the capsule, imprinted with Lilly on the cap and 3004 and 90 mg on the body
4 CONTRAINDICATIONS
When using PROZAC and olanzapine in combination, also refer to the Contraindications section of the package insert for
Symbyax.
The use of PROZAC is contraindicated with the following:
• Monoamine Oxidase Inhibitors [see Drug Interactions (7.1)]
• Pimozide [see Drug Interactions (7.9)]
• Thioridazine [see Drug Interactions (7.9)]
5 WARNINGS AND PRECAUTIONS
When using PROZAC and olanzapine in combination, also refer to the Warnings and Precautions section of the package
insert for Symbyax.
5.1 Clinical Worsening and Suicide Risk
Patients with Major Depressive Disorder (MDD), both adult and pediatric, may experience worsening of their depression
and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking

7
antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and
certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a
long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of
suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of
antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults (ages 18-24) with Major Depressive Disorder (MDD) and other psychiatric disorders.
Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age
24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.
The pooled analyses of placebo-controlled trials in children and adolescents with MDD, Obsessive Compulsive Disorder
(OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The
pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials
(median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of
suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences
in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences
(drug versus placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo
difference in the number of cases of suicidality per 1000 patients treated) are provided in Table 2.
Table 2: Suicidality per 1000 Patients Treated

Age Range Drug-Placebo Difference in Number of Cases of Suicidality
per 1000 Patients Treated
Increases Compared to Placebo
<18 14 additional cases
18-24 5 additional cases
Decreases Compared to Placebo
25-64 1 fewer case
≥65 6 fewer cases
No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to
reach any conclusion about drug effect on suicide.
It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is
substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the
recurrence of depression.
All patients being treated with antidepressants for any indication should be monitored appropriately and observed
closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course
of drug therapy, or at times of dose changes, either increases or decreases.
The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity,
akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with
antidepressants for Major Depressive Disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal
link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has
not been established, there is concern that such symptoms may represent precursors to emerging suicidality.
Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in
patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to
worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient’s
presenting symptoms.
If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with
recognition that abrupt discontinuation can be associated with certain symptoms [see Warnings and Precautions (5.13)].
Families and caregivers of patients being treated with antidepressants for Major Depressive Disorder or other
indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of
agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of
suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily
observation by families and caregivers. Prescriptions for PROZAC should be written for the smallest quantity of capsules consistent
with good patient management, in order to reduce the risk of overdose.
It should be noted that PROZAC is approved in the pediatric population only for Major Depressive Disorder and Obsessive
Compulsive Disorder. Safety and effectiveness of PROZAC and olanzapine in combination in patients less than 18 years of age have
not been established.
5.2 Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions
The development of a potentially life-threatening serotonin syndrome or neuroleptic malignant syndrome (NMS)-like
reactions have been reported with SNRIs and SSRIs alone, including PROZAC treatment, but particularly with concomitant use of

8
serotonergic drugs (including triptans), with drugs which impair metabolism of serotonin (including MAOIs), or with antipsychotics
or other dopamine antagonists. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations,
coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia,
incoordination), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Serotonin syndrome, in its most severe form, can
resemble neuroleptic malignant syndrome which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid
fluctuation of vital signs, and mental status changes. Patients should be monitored for the emergence of serotonin syndrome or NMS-
like signs and symptoms.
The concomitant use of PROZAC with MAOIs intended to treat depression is contraindicated [see Contraindications (4) and
Drug Interactions (7.1)].
If concomitant treatment of PROZAC with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful
observation of the patient is advised, particularly during treatment initiation and dose increases [see Drug Interactions (7.4)].
The concomitant use of PROZAC with serotonin precursors (such as tryptophan) is not recommended [see Drug Interactions
(7.3)].
Treatment with fluoxetine and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be
discontinued immediately if the above reactions occur and supportive symptomatic treatment should be initiated.
In US fluoxetine clinical trials, 7% of 10,782 patients developed various types of rashes and/or urticaria. Among the cases of
rash and/or urticaria reported in premarketing clinical trials, almost a third were withdrawn from treatment because of the rash and/or
systemic signs or symptoms associated with the rash. Clinical findings reported in association with rash include fever, leukocytosis,
arthralgias, edema, carpal tunnel syndrome, respiratory distress, lymphadenopathy, proteinuria, and mild transaminase elevation. Most
patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all
patients experiencing these reactions were reported to recover completely.
In premarketing clinical trials, 2 patients are known to have developed a serious cutaneous systemic illness. In neither patient
was there an unequivocal diagnosis, but one was considered to have a leukocytoclastic vasculitis, and the other, a severe desquamating
syndrome that was considered variously to be a vasculitis or erythema multiforme. Other patients have had systemic syndromes
suggestive of serum sickness.
Since the introduction of PROZAC, systemic reactions, possibly related to vasculitis and including lupus-like syndrome, have
developed in patients with rash. Although these reactions are rare, they may be serious, involving the lung, kidney, or liver. Death has
been reported to occur in association with these systemic reactions.
Anaphylactoid reactions, including bronchospasm, angioedema, laryngospasm, and urticaria alone and in combination, have
been reported.
Pulmonary reactions, including inflammatory processes of varying histopathology and/or fibrosis, have been reported rarely.
These reactions have occurred with dyspnea as the only preceding symptom.
Whether these systemic reactions and rash have a common underlying cause or are due to different etiologies or pathogenic
processes is not known. Furthermore, a specific underlying immunologic basis for these reactions has not been identified. Upon the
appearance of rash or of other possibly allergic phenomena for which an alternative etiology cannot be identified, PROZAC should be
discontinued.
5.4 Screening Patients for Bipolar Disorder and Monitoring for Mania/Hypomania
A major depressive episode may be the initial presentation of Bipolar Disorder. It is generally believed (though not established
in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a
mixed/manic episode in patients at risk for Bipolar Disorder. Whether any of the symptoms described for clinical worsening and
suicide risk represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with
depressive symptoms should be adequately screened to determine if they are at risk for Bipolar Disorder; such screening should
include a detailed psychiatric history, including a family history of suicide, Bipolar Disorder, and depression. It should be noted that
PROZAC and olanzapine in combination is approved for the acute treatment of depressive episodes associated with Bipolar I Disorder
[see Warnings and Precautions section of the package insert for Symbyax]. PROZAC monotherapy is not indicated for the treatment
of depressive episodes associated with Bipolar I Disorder.
In US placebo-controlled clinical trials for Major Depressive Disorder, mania/hypomania was reported in 0.1% of patients
treated with PROZAC and 0.1% of patients treated with placebo. Activation of mania/hypomania has also been reported in a small
proportion of patients with Major Affective Disorder treated with other marketed drugs effective in the treatment of Major Depressive
Disorder [see Use in Specific Populations (8.4)].
In US placebo-controlled clinical trials for OCD, mania/hypomania was reported in 0.8% of patients treated with PROZAC
and no patients treated with placebo. No patients reported mania/hypomania in US placebo-controlled clinical trials for bulimia. In
US PROZAC clinical trials, 0.7% of 10,782 patients reported mania/hypomania [see Use in Specific Populations (8.4)].
5.5 Seizures
In US placebo-controlled clinical trials for Major Depressive Disorder, convulsions (or reactions described as possibly having
been seizures) were reported in 0.1% of patients treated with PROZAC and 0.2% of patients treated with placebo. No patients reported
convulsions in US placebo-controlled clinical trials for either OCD or bulimia. In US PROZAC clinical trials, 0.2% of 10,782 patients

9
reported convulsions. The percentage appears to be similar to that associated with other marketed drugs effective in the treatment of
Major Depressive Disorder. PROZAC should be introduced with care in patients with a history of seizures.
5.6 Altered Appetite and Weight
Significant weight loss, especially in underweight depressed or bulimic patients, may be an undesirable result of treatment
with PROZAC.
In US placebo-controlled clinical trials for Major Depressive Disorder, 11% of patients treated with PROZAC and 2% of
patients treated with placebo reported anorexia (decreased appetite). Weight loss was reported in 1.4% of patients treated with
PROZAC and in 0.5% of patients treated with placebo. However, only rarely have patients discontinued treatment with PROZAC
because of anorexia or weight loss [see Use in Specific Populations (8.4)].
In US placebo-controlled clinical trials for OCD, 17% of patients treated with PROZAC and 10% of patients treated with
placebo reported anorexia (decreased appetite). One patient discontinued treatment with PROZAC because of anorexia [see Use in
Specific Populations (8.4)].
In US placebo-controlled clinical trials for Bulimia Nervosa, 8% of patients treated with PROZAC 60 mg and 4% of patients
treated with placebo reported anorexia (decreased appetite). Patients treated with PROZAC 60 mg on average lost 0.45 kg compared
with a gain of 0.16 kg by patients treated with placebo in the 16-week double-blind trial. Weight change should be monitored during
therapy.
5.7 Abnormal Bleeding
SNRIs and SSRIs, including fluoxetine, may increase the risk of bleeding reactions. Concomitant use of aspirin, nonsteroidal
anti-inflammatory drugs, warfarin, and other anti-coagulants may add to this risk. Case reports and epidemiological studies (case
control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the
occurrence of gastrointestinal bleeding. Bleeding reactions related to SNRIs and SSRIs use have ranged from ecchymoses,
hematomas, epistaxis, and petechiae to life-threatening hemorrhages.
Patients should be cautioned about the risk of bleeding associated with the concomitant use of fluoxetine and NSAIDs,
aspirin, warfarin, or other drugs that affect coagulation [see Drug Interactions (7.6)].
5.8 Hyponatremia
Hyponatremia has been reported during treatment with SNRIs and SSRIs, including PROZAC. In many cases, this
hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum
sodium lower than 110 mmol/L have been reported and appeared to be reversible when PROZAC was discontinued. Elderly patients
may be at greater risk of developing hyponatremia with SNRIs and SSRIs. Also, patients taking diuretics or who are otherwise volume
depleted may be at greater risk [see Use in Specific Populations (8.5)]. Discontinuation of PROZAC should be considered in patients
with symptomatic hyponatremia and appropriate medical intervention should be instituted.
Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness,
and unsteadiness, which may lead to falls. More severe and/or acute cases have been associated with hallucination, syncope, seizure,
coma, respiratory arrest, and death.
5.9 Anxiety and Insomnia
In US placebo-controlled clinical trials for Major Depressive Disorder, 12% to 16% of patients treated with PROZAC and 7%
to 9% of patients treated with placebo reported anxiety, nervousness, or insomnia.
In US placebo-controlled clinical trials for OCD, insomnia was reported in 28% of patients treated with PROZAC and in 22%
of patients treated with placebo. Anxiety was reported in 14% of patients treated with PROZAC and in 7% of patients treated with
placebo.
In US placebo-controlled clinical trials for Bulimia Nervosa, insomnia was reported in 33% of patients treated with PROZAC
60 mg, and 13% of patients treated with placebo. Anxiety and nervousness were reported, respectively, in 15% and 11% of patients
treated with PROZAC 60 mg and in 9% and 5% of patients treated with placebo.
Among the most common adverse reactions associated with discontinuation (incidence at least twice that for placebo and at
least 1% for PROZAC in clinical trials collecting only a primary reaction associated with discontinuation) in US placebo-controlled
fluoxetine clinical trials were anxiety (2% in OCD), insomnia (1% in combined indications and 2% in bulimia), and nervousness
(1% in Major Depressive Disorder) [see Table 5].
5.10 Use in Patients with Concomitant Illness
Clinical experience with PROZAC in patients with concomitant systemic illness is limited. Caution is advisable in using
PROZAC in patients with diseases or conditions that could affect metabolism or hemodynamic responses.
Cardiovascular — Fluoxetine has not been evaluated or used to any appreciable extent in patients with a recent history of
myocardial infarction or unstable heart disease. Patients with these diagnoses were systematically excluded from clinical studies
during the product’s premarket testing. However, the electrocardiograms of 312 patients who received PROZAC in double-blind trials
were retrospectively evaluated; no conduction abnormalities that resulted in heart block were observed. The mean heart rate was
reduced by approximately 3 beats/min.
Glycemic Control — In patients with diabetes, PROZAC may alter glycemic control. Hypoglycemia has occurred during
therapy with PROZAC, and hyperglycemia has developed following discontinuation of the drug. As is true with many other types of

10
medication when taken concurrently by patients with diabetes, insulin and/or oral hypoglycemic, dosage may need to be adjusted
when therapy with PROZAC is instituted or discontinued.
5.11 Potential for Cognitive and Motor Impairment
As with any CNS-active drug, PROZAC has the potential to impair judgment, thinking, or motor skills. Patients should be
cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that the drug treatment does
not affect them adversely.
5.12 Long Elimination Half-Life
Because of the long elimination half-lives of the parent drug and its major active metabolite, changes in dose will not be fully
reflected in plasma for several weeks, affecting both strategies for titration to final dose and withdrawal from treatment. This is of
potential consequence when drug discontinuation is required or when drugs are prescribed that might interact with fluoxetine and
norfluoxetine following the discontinuation of fluoxetine [see Clinical Pharmacology (12.3)].
During marketing of PROZAC, SNRIs, and SSRIs, there have been spontaneous reports of adverse reactions occurring upon
discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness,
sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability,
insomnia, and hypomania. While these reactions are generally self-limiting, there have been reports of serious discontinuation
symptoms. Patients should be monitored for these symptoms when discontinuing treatment with PROZAC. A gradual reduction in the
dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose
or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician
may continue decreasing the dose but at a more gradual rate. Plasma fluoxetine and norfluoxetine concentration decrease gradually at
the conclusion of therapy which may minimize the risk of discontinuation symptoms with this drug.
5.14 PROZAC and Olanzapine in Combination
When using PROZAC and olanzapine in combination, also refer to the Warnings and Precautions section of the package
insert for Symbyax.
6 ADVERSE REACTIONS
When using PROZAC and olanzapine in combination, also refer to the Adverse Reactions section of the package insert for
Symbyax.
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a
drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in
practice.
Multiple doses of PROZAC have been administered to 10,782 patients with various diagnoses in US clinical trials. In
addition, there have been 425 patients administered PROZAC in panic clinical trials. Adverse reactions were recorded by clinical
investigators using descriptive terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of
the proportion of individuals experiencing adverse reactions without first grouping similar types of reactions into a limited (i.e.,
reduced) number of standardized reaction categories.
In the tables and tabulations that follow, COSTART Dictionary terminology has been used to classify reported adverse
reactions. The stated frequencies represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse
reaction of the type listed. A reaction was considered treatment-emergent if it occurred for the first time or worsened while receiving
therapy following baseline evaluation. It is important to emphasize that reactions reported during therapy were not necessarily caused
by it.
The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side
effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the
clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving
different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for
estimating the relative contribution of drug and nondrug factors to the side effect incidence rate in the population studied.
Incidence in Major Depressive Disorder, OCD, bulimia, and Panic Disorder placebo-controlled clinical trials (excluding
data from extensions of trials) — Table 3 enumerates the most common treatment-emergent adverse reactions associated with the use
of PROZAC (incidence of at least 5% for PROZAC and at least twice that for placebo within at least 1 of the indications) for the
treatment of Major Depressive Disorder, OCD, and bulimia in US controlled clinical trials and Panic Disorder in US plus non-US
controlled trials. Table 5 enumerates treatment-emergent adverse reactions that occurred in 2% or more patients treated with PROZAC
and with incidence greater than placebo who participated in US Major Depressive Disorder, OCD, and bulimia controlled clinical
trials and US plus non-US Panic Disorder controlled clinical trials. Table 4 provides combined data for the pool of studies that are
provided separately by indication in Table 3.

11
Table 3: Most Common Treatment-Emergent Adverse Reactions: Incidence in Major Depressive Disorder, OCD, Bulimia,
and Panic Disorder Placebo-Controlled Clinical Trials1,2
Percentage of Patients Reporting Event
Major Depressive
Disorder OCD Bulimia Panic Disorder
Body System/ PROZAC Placebo PROZAC Placebo PROZAC Placebo PROZAC Placebo
Adverse (N=1728) (N=975) (N=266) (N=89) (N=450) (N=267) (N=425) (N=342)
Reaction
Body as a
Whole
Asthenia 9 5 15 11 21 9 7 7
Flu syndrome 3 4 10 7 8 3 5 5
Cardiovascular
System
Vasodilatation 3 2 5 - 2 1 1 -
Digestive
System
Nausea 21 9 26 13 29 11 12 7
Diarrhea 12 8 18 13 8 6 9 4
Anorexia 11 2 17 10 8 4 4 1
Dry mouth 10 7 12 3 9 6 4 4
Dyspepsia 7 5 10 4 10 6 6 2
Nervous System
Insomnia 16 9 28 22 33 13 10 7
Anxiety 12 7 14 7 15 9 6 2
Nervousness 14 9 14 15 11 5 8 6
Somnolence 13 6 17 7 13 5 5 2
Tremor 10 3 9 1 13 1 3 1
Libido 3 - 11 2 5 1 1 2
decreased
Abnormal 1 1 5 2 5 3 1 1
dreams
Respiratory
System
Pharyngitis 3 3 11 9 10 5 3 3
Sinusitis 1 4 5 2 6 4 2 3
Yawn -- -- 7 -- 11 -- 1 --
Skin and
Appendages
Sweating 8 3 7 - 8 3 2 2
Rash 4 3 6 3 4 4 2 2
Urogenital
System
Impotence3 2 -- -- -- 7 -- 1 --
Abnormal
ejaculation3 -- -- 7 -- 7 -- 2 1
1
Incidence less than 1%.
2
Includes US data for Major Depressive Disorder, OCD, Bulimia, and Panic Disorder clinical trials, plus non-US data for Panic
Disorder clinical trials.
3
Denominator used was for males only (N=690 PROZAC Major Depressive Disorder; N=410 placebo Major Depressive Disorder;
N=116 PROZAC OCD; N=43 placebo OCD; N=14 PROZAC bulimia; N=1 placebo bulimia; N=162 PROZAC panic; N=121
placebo panic).
Table 4: Treatment-Emergent Adverse Reactions: Incidence in Major Depressive Disorder, OCD, Bulimia, and Panic
Disorder Placebo-Controlled Clinical Trials1,2
Percentage of Patients Reporting Event

Major Depressive Disorder, OCD, Bulimia,

12
and Panic Disorder Combined

Body System/ PROZAC Placebo
Adverse Reaction (N=2869) (N=1673)
Body as a Whole
Headache 21 19
Asthenia 11 6
Flu syndrome 5 4
Fever 2 1
Cardiovascular System
Vasodilatation 2 1
Digestive System
Nausea 22 9
Diarrhea 11 7
Anorexia 10 3
Dry mouth 9 6
Dyspepsia 8 4
Constipation 5 4
Flatulence 3 2
Vomiting 3 2
Metabolic and Nutritional
Disorders
Weight loss 2 1
Nervous System
Insomnia 19 10
Nervousness 13 8
Anxiety 12 6
Somnolence 12 5
Dizziness 9 6
Tremor 9 2
Libido decreased 4 1
Thinking abnormal 2 1
Respiratory System
Yawn 3 --
Skin and Appendages
Sweating 7 3
Rash 4 3
Pruritus 3 2
Special Senses
Abnormal vision 2 1
1
Incidence less than 1%.
2
Includes US data for Major Depressive Disorder, OCD, bulimia, and Panic Disorder clinical trials, plus non-US data for Panic
Disorder clinical trials.
Associated with discontinuation in Major Depressive Disorder, OCD, bulimia, and Panic Disorder placebo-controlled
clinical trials (excluding data from extensions of trials) — Table 5 lists the adverse reactions associated with discontinuation of
PROZAC treatment (incidence at least twice that for placebo and at least 1% for PROZAC in clinical trials collecting only a primary
reaction associated with discontinuation) in Major Depressive Disorder, OCD, bulimia, and Panic Disorder clinical trials, plus non-US
Panic Disorder clinical trials.
Table 5: Most Common Adverse Reactions Associated with Discontinuation in Major Depressive Disorder, OCD, Bulimia, and
Panic Disorder Placebo-Controlled Clinical Trials1
Major Depressive
Disorder, OCD, Major
Bulimia, and Panic Depressive
Disorder Combined Disorder OCD Bulimia Panic Disorder
(N=1533) (N=392) (N=266) (N=450) (N=425)

13
Anxiety (1%) -- Anxiety (2%) -- Anxiety (2%)

-- -- -- Insomnia (2%) --
- Nervousness (1%) - - Nervousness (1%)
-- -- Rash (1%) -- --
1
Includes US Major Depressive Disorder, OCD, bulimia, and Panic Disorder clinical trials, plus non-US Panic Disorder clinical
trials.
Other adverse reactions in pediatric patients (children and adolescents) — Treatment-emergent adverse reactions were
collected in 322 pediatric patients (180 fluoxetine-treated, 142 placebo-treated). The overall profile of adverse reactions was generally
similar to that seen in adult studies, as shown in Tables 4 and 5. However, the following adverse reactions (excluding those which
appear in the body or footnotes of Tables 4 and 5 and those for which the COSTART terms were uninformative or misleading) were
reported at an incidence of at least 2% for fluoxetine and greater than placebo: thirst, hyperkinesia, agitation, personality disorder,
epistaxis, urinary frequency, and menorrhagia.
The most common adverse reaction (incidence at least 1% for fluoxetine and greater than placebo) associated with
discontinuation in 3 pediatric placebo-controlled trials (N=418 randomized; 228 fluoxetine-treated; 190 placebo-treated) was
mania/hypomania (1.8% for fluoxetine-treated, 0% for placebo-treated). In these clinical trials, only a primary reaction associated with
discontinuation was collected.
Reactions observed in PROZAC Weekly clinical trials — Treatment-emergent adverse reactions in clinical trials with
PROZAC Weekly were similar to the adverse reactions reported by patients in clinical trials with PROZAC daily. In a
placebo-controlled clinical trial, more patients taking PROZAC Weekly reported diarrhea than patients taking placebo
(10% versus 3%, respectively) or taking PROZAC 20 mg daily (10% versus 5%, respectively).
Male and female sexual dysfunction with SSRIs — Although changes in sexual desire, sexual performance, and sexual
satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of pharmacologic treatment. In
particular, some evidence suggests that SSRIs can cause such untoward sexual experiences. Reliable estimates of the incidence and
severity of untoward experiences involving sexual desire, performance, and satisfaction are difficult to obtain, however, in part
because patients and physicians may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual
experience and performance, cited in product labeling, are likely to underestimate their actual incidence. In patients enrolled in
US Major Depressive Disorder, OCD, and bulimia placebo-controlled clinical trials, decreased libido was the only sexual side effect
reported by at least 2% of patients taking fluoxetine (4% fluoxetine, <1% placebo). There have been spontaneous reports in women
taking fluoxetine of orgasmic dysfunction, including anorgasmia.
There are no adequate and well-controlled studies examining sexual dysfunction with fluoxetine treatment.
Priapism has been reported with all SSRIs.
While it is difficult to know the precise risk of sexual dysfunction associated with the use of SSRIs, physicians should
routinely inquire about such possible side effects.
6.2 Other Reactions
Following is a list of treatment-emergent adverse reactions reported by patients treated with fluoxetine in clinical trials. This
listing is not intended to include reactions (1) already listed in previous tables or elsewhere in labeling, (2) for which a drug cause was
remote, (3) which were so general as to be uninformative, (4) which were not considered to have significant clinical implications, or
(5) which occurred at a rate equal to or less than placebo.
Reactions are classified by body system using the following definitions: frequent adverse reactions are those occurring in at
least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; rare reactions are those occurring in
fewer than 1/1000 patients.
Body as a Whole — Frequent: chills; Infrequent: suicide attempt; Rare: acute abdominal syndrome, photosensitivity
reaction.
Cardiovascular System — Frequent: palpitation; Infrequent: arrhythmia, hypotension1.
Digestive System — Infrequent: dysphagia, gastritis, gastroenteritis, melena, stomach ulcer; Rare: bloody diarrhea, duodenal
ulcer, esophageal ulcer, gastrointestinal hemorrhage, hematemesis, hepatitis, peptic ulcer, stomach ulcer hemorrhage.
Hemic and Lymphatic System — Infrequent: ecchymosis; Rare: petechia, purpura.
Nervous System — Frequent: emotional lability; Infrequent: akathisia, ataxia, balance disorder1, bruxism1, buccoglossal
syndrome, depersonalization, euphoria, hypertonia, libido increased, myoclonus, paranoid reaction; Rare: delusions.
Respiratory System — Rare: larynx edema.
Skin and Appendages — Infrequent: alopecia; Rare: purpuric rash.
Special Senses — Frequent: taste perversion; Infrequent: mydriasis.
Urogenital System — Frequent: micturition disorder; Infrequent: dysuria, gynecological bleeding2.
1
MedDRA dictionary term from integrated database of placebo controlled trials of 15870 patients, of which 9673 patients received
fluoxetine.

14
2
Group term that includes individual MedDRA terms: cervix hemorrhage uterine, dysfunctional uterine bleeding, genital
hemorrhage, menometrorrhagia, menorrhagia, metrorrhagia, polymenorrhea, postmenopausal hemorrhage, uterine hemorrhage,
vaginal hemorrhage. Adjusted for gender.
6.3 Postmarketing Experience
The following adverse reactions have been identified during post approval use of PROZAC. Because these reactions are
reported voluntarily from a population of uncertain size, it is difficult to reliably estimate their frequency or evaluate a causal
relationship to drug exposure.
Voluntary reports of adverse reactions temporally associated with PROZAC that have been received since market introduction
and that may have no causal relationship with the drug include the following: aplastic anemia, atrial fibrillation1, cataract,
cerebrovascular accident1, cholestatic jaundice, dyskinesia (including, for example, a case of buccal-lingual-masticatory syndrome
with involuntary tongue protrusion reported to develop in a 77-year-old female after 5 weeks of fluoxetine therapy and which
completely resolved over the next few months following drug discontinuation), eosinophilic pneumonia1, epidermal necrolysis,
erythema multiforme, erythema nodosum, exfoliative dermatitis, gynecomastia, heart arrest1, hepatic failure/necrosis,
hyperprolactinemia, hypoglycemia, immune-related hemolytic anemia, kidney failure, movement disorders developing in patients with
risk factors including drugs associated with such reactions and worsening of pre-existing movement disorders, optic neuritis,
pancreatitis1, pancytopenia, pulmonary embolism, pulmonary hypertension, QT prolongation, Stevens-Johnson syndrome,
thrombocytopenia1, thrombocytopenic purpura, ventricular tachycardia (including torsades de pointes–type arrhythmias), vaginal
bleeding, and violent behaviors1.
1
These terms represent serious adverse events, but do not meet the definition for adverse drug reactions. They are included here
because of their seriousness.
7 DRUG INTERACTIONS
As with all drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, pharmacokinetic drug
inhibition or enhancement, etc.) is a possibility.
7.1 Monoamine Oxidase Inhibitors (MAOI)
There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic
instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to
delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who
have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic
malignant syndrome. Therefore, PROZAC should not be used in combination with an MAOI, or within a minimum of 14 days of
discontinuing therapy with an MAOI [see Contraindications (4)]. Since fluoxetine and its major metabolite have very long
elimination half-lives, at least 5 weeks (perhaps longer, especially if fluoxetine has been prescribed chronically and/or at higher doses)
should be allowed after stopping PROZAC before starting an MAOI [see Clinical Pharmacology (12.3)].
7.2 CNS Acting Drugs
Caution is advised if the concomitant administration of PROZAC and such drugs is required. In evaluating individual cases,
consideration should be given to using lower initial doses of the concomitantly administered drugs, using conservative titration
schedules, and monitoring of clinical status [see Clinical Pharmacology (12.3)].
7.3 Serotonergic Drugs
Based on the mechanism of action of SNRIs and SSRIs, including PROZAC, and the potential for serotonin syndrome,
caution is advised when PROZAC is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such
as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John’s Wort [see Warnings
and Precautions (5.2)]. The concomitant use of PROZAC with SNRIs, SSRIs, or tryptophan is not recommended [see Drug
Interactions (7.4), (7.5)].
7.4 Triptans
There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan. If concomitant treatment
of PROZAC with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation
and dose increases [see Warnings and Precautions (5.2) and Drug Interactions (7.3)].
7.5 Tryptophan
Five patients receiving PROZAC in combination with tryptophan experienced adverse reactions, including agitation,
restlessness, and gastrointestinal distress. The concomitant use with tryptophan is not recommended [see Warnings and Precautions
(5.2) and Drug Interactions (7.3)].
7.6 Drugs that Interfere with Hemostasis (e.g., NSAIDS, Aspirin, Warfarin)
Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort
design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the
occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of
bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SNRIs or SSRIs are coadministered

15
with warfarin. Patients receiving warfarin therapy should be carefully monitored when fluoxetine is initiated or discontinued [see
Warnings and Precautions (5.7)].
7.7 Electroconvulsive Therapy (ECT)
There are no clinical studies establishing the benefit of the combined use of ECT and fluoxetine. There have been rare reports
of prolonged seizures in patients on fluoxetine receiving ECT treatment.
7.8 Potential for Other Drugs to affect PROZAC
Drugs Tightly Bound to Plasma Proteins — Because fluoxetine is tightly bound to plasma proteins, adverse effects may result
from displacement of protein-bound fluoxetine by other tightly-bound drugs [see Clinical Pharmacology (12.3)].
7.9 Potential for PROZAC to affect Other Drugs
Pimozide — Concomitant use in patients taking pimozide is contraindicated. Clinical studies of pimozide with other
antidepressants demonstrate an increase in drug interaction or QTc prolongation. While a specific study with pimozide and fluoxetine
has not been conducted, the potential for drug interactions or QTc prolongation warrants restricting the concurrent use of pimozide and
PROZAC [see Contraindications (4)].
Thioridazine — Thioridazine should not be administered with PROZAC or within a minimum of 5 weeks after PROZAC has
been discontinued [see Contraindications (4)].
In a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators of debrisoquin, a single 25 mg oral
dose of thioridazine produced a 2.4-fold higher Cmax and a 4.5-fold higher AUC for thioridazine in the slow hydroxylators compared
with the rapid hydroxylators. The rate of debrisoquin hydroxylation is felt to depend on the level of CYP2D6 isozyme activity. Thus,
this study suggests that drugs which inhibit CYP2D6, such as certain SSRIs, including fluoxetine, will produce elevated plasma levels
of thioridazine.
Thioridazine administration produces a dose-related prolongation of the QTc interval, which is associated with serious
ventricular arrhythmias, such as torsades de pointes-type arrhythmias, and sudden death. This risk is expected to increase with
fluoxetine-induced inhibition of thioridazine metabolism.
Drugs Metabolized by CYP2D6 — Fluoxetine inhibits the activity of CYP2D6, and may make individuals with normal
CYP2D6 metabolic activity resemble a poor metabolizer. Coadministration of fluoxetine with other drugs that are metabolized by
CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics
(e.g., propafenone, flecainide, and others) should be approached with caution. Therapy with medications that are predominantly
metabolized by the CYP2D6 system and that have a relatively narrow therapeutic index (see list below) should be initiated at the low
end of the dose range if a patient is receiving fluoxetine concurrently or has taken it in the previous 5 weeks. Thus, his/her dosing
requirements resemble those of poor metabolizers. If fluoxetine is added to the treatment regimen of a patient already receiving a drug
metabolized by CYP2D6, the need for decreased dose of the original medication should be considered. Drugs with a narrow
therapeutic index represent the greatest concern (e.g., flecainide, propafenone, vinblastine, and TCAs). Due to the risk of serious
ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, thioridazine should not be
administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued [see Contraindications (4)].
Tricyclic Antidepressants (TCAs) — In 2 studies, previously stable plasma levels of imipramine and desipramine have
increased greater than 2- to 10-fold when fluoxetine has been administered in combination. This influence may persist for 3 weeks or
longer after fluoxetine is discontinued. Thus, the dose of TCAs may need to be reduced and plasma TCA concentrations may need to
be monitored temporarily when fluoxetine is coadministered or has been recently discontinued [see Clinical Pharmacology (12.3)].
Benzodiazapines — The half-life of concurrently administered diazepam may be prolonged in some patients [see Clinical
Pharmacology (12.3)]. Coadministration of alprazolam and fluoxetine has resulted in increased alprazolam plasma concentrations and
in further psychomotor performance decrement due to increased alprazolam levels.
Antipsychotics — Some clinical data suggests a possible pharmacodynamic and/or pharmacokinetic interaction between SSRIs
and antipsychotics. Elevation of blood levels of haloperidol and clozapine has been observed in patients receiving concomitant
fluoxetine [see Contraindications (4)].
Anticonvulsants — Patients on stable doses of phenytoin and carbamazepine have developed elevated plasma anticonvulsant
concentrations and clinical anticonvulsant toxicity following initiation of concomitant fluoxetine treatment.
Lithium — There have been reports of both increased and decreased lithium levels when lithium was used concomitantly with
fluoxetine. Cases of lithium toxicity and increased serotonergic effects have been reported. Lithium levels should be monitored when
these drugs are administered concomitantly.
Drugs Tightly Bound to Plasma Proteins — Because fluoxetine is tightly bound to plasma proteins, the administration of
fluoxetine to a patient taking another drug that is tightly bound to protein (e.g., Coumadin, digitoxin) may cause a shift in plasma
concentrations potentially resulting in an adverse effect [see Clinical Pharmacology (12.3)].
Drugs Metabolized by CYP3A4 — In an in vivo interaction study involving coadministration of fluoxetine with single doses of
terfenadine (a CYP3A4 substrate), no increase in plasma terfenadine concentrations occurred with concomitant fluoxetine.
Additionally, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more
potent than fluoxetine or norfluoxetine as an inhibitor of the metabolism of several substrates for this enzyme, including astemizole,
cisapride, and midazolam. These data indicate that fluoxetine’s extent of inhibition of CYP3A4 activity is not likely to be of clinical
significance.

16
Olanzapine— Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the
maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. The magnitude of the impact of this
factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely
recommended.
When using PROZAC and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for
Symbyax.
8 USE IN SPECIFIC POPULATIONS
When using PROZAC and olanzapine in combination, also refer to the Use in Specific Populations section of the package
insert for Symbyax.
8.1 Pregnancy
Pregnancy Category C — PROZAC should be used during pregnancy only if the potential benefit justifies the potential risk to
the fetus. All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure.
Treatment of Pregnant Women during the First Trimester — There are no adequate and well-controlled clinical studies on the
use of fluoxetine in pregnant women. Results of a number of published epidemiological studies assessing the risk of fluoxetine
exposure during the first trimester of pregnancy have demonstrated inconsistent results. More than 10 cohort studies and case-control
studies failed to demonstrate an increased risk for congenital malformations overall. However, one prospective cohort study conducted
by the European Network of Teratology Information Services reported an increased risk of cardiovascular malformations in infants
born to women (N = 253) exposed to fluoxetine during the first trimester of pregnancy compared to infants of women (N = 1,359)
who were not exposed to fluoxetine. There was no specific pattern of cardiovascular malformations. Overall, however, a causal
relationship has not been established.
Treatment of Pregnant Women during the Third Trimester — Neonates exposed to PROZAC, SNRIs, or SSRIs late in the
third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such
complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea,
seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness,
irritability, and constant crying. These features are consistent with either a direct toxic effect of SNRIs and SSRIs or, possibly, a drug
discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome.
Infants exposed to SSRIs in late pregnancy may have an increased risk for persistent pulmonary hypertension of the newborn
(PPHN). PPHN occurs in 1 to 2 per 1000 live births in the general population and is associated with substantial neonatal morbidity
and mortality. In a retrospective case-control study of 377 women whose infants were born with PPHN and 836 women whose infants
were born healthy, the risk for developing PPHN was approximately six-fold higher for infants exposed to SSRIs after the 20th week
of gestation compared to infants who had not been exposed to antidepressants during pregnancy. There is currently no corroborative
evidence regarding the risk for PPHN following exposure to SSRIs in pregnancy; this is the first study that has investigated the
potential risk. The study did not include enough cases with exposure to individual SSRIs to determine if all SSRIs posed similar levels
of PPHN risk.
Clinical Considerations — When treating pregnant women with PROZAC, the physician should carefully consider both the
potential risks and potential benefits of treatment, taking into account the risk of untreated depression during pregnancy. Physicians
should note that in a prospective longitudinal study of 201 women with a history of major depression who were euthymic at the
beginning of pregnancy, women who discontinued antidepressant medication during pregnancy were more likely to experience a
relapse of major depression than women who continued antidepressant medication.
The physician may consider tapering PROZAC in the third trimester [see Dosage and Administration (2.7)].
Animal Data — In embryo-fetal development studies in rats and rabbits, there was no evidence of teratogenicity following
administration of fluoxetine at doses up to 12.5 and 15 mg/kg/day, respectively (1.5 and 3.6 times, respectively, the maximum
recommended human dose (MRHD) of 80 mg on a mg/m2 basis) throughout organogenesis. However, in rat reproduction studies, an
increase in stillborn pups, a decrease in pup weight, and an increase in pup deaths during the first 7 days postpartum occurred
following maternal exposure to 12 mg/kg/day (1.5 times the MRHD on a mg/m2 basis) during gestation or 7.5 mg/kg/day (0.9 times
the MRHD on a mg/m2 basis) during gestation and lactation. There was no evidence of developmental neurotoxicity in the surviving
offspring of rats treated with 12 mg/kg/day during gestation. The no-effect dose for rat pup mortality was 5 mg/kg/day (0.6 times the
MRHD on a mg/m2 basis).
8.2 Labor and Delivery
The effect of PROZAC on labor and delivery in humans is unknown. However, because fluoxetine crosses the placenta and
because of the possibility that fluoxetine may have adverse effects on the newborn, fluoxetine should be used during labor and
delivery only if the potential benefit justifies the potential risk to the fetus.
8.3 Nursing Mothers
Because PROZAC is excreted in human milk, nursing while on PROZAC is not recommended. In one breast-milk sample, the
concentration of fluoxetine plus norfluoxetine was 70.4 ng/mL. The concentration in the mother’s plasma was 295.0 ng/mL. No
adverse effects on the infant were reported. In another case, an infant nursed by a mother on PROZAC developed crying, sleep

17
disturbance, vomiting, and watery stools. The infant’s plasma drug levels were 340 ng/mL of fluoxetine and 208 ng/mL of
norfluoxetine on the second day of feeding.
8.4 Pediatric Use
The efficacy of PROZAC for the treatment of Major Depressive Disorder was demonstrated in two 8- to 9-week
placebo-controlled clinical trials with 315 pediatric outpatients ages 8 to ≤18 [see Clinical Studies (14.1)].
The efficacy of PROZAC for the treatment of OCD was demonstrated in one 13-week placebo-controlled clinical trial with
103 pediatric outpatients ages 7 to <18 [see Clinical Studies (14.2)].
The safety and effectiveness in pediatric patients <8 years of age in Major Depressive Disorder and <7 years of age in OCD
have not been established.
Fluoxetine pharmacokinetics were evaluated in 21 pediatric patients (ages 6 to ≤18) with Major Depressive Disorder or OCD
[see Clinical Pharmacology (12.3)].
The acute adverse reaction profiles observed in the 3 studies (N=418 randomized; 228 fluoxetine-treated, 190 placebo-treated)
were generally similar to that observed in adult studies with fluoxetine. The longer-term adverse reaction profile observed in the
19-week Major Depressive Disorder study (N=219 randomized; 109 fluoxetine-treated, 110 placebo-treated) was also similar to that
observed in adult trials with fluoxetine [see Adverse Reactions (6.1)].
Manic reaction, including mania and hypomania, was reported in 6 (1 mania, 5 hypomania) out of 228 (2.6%)
fluoxetine-treated patients and in 0 out of 190 (0%) placebo-treated patients. Mania/hypomania led to the discontinuation of 4 (1.8%)
fluoxetine-treated patients from the acute phases of the 3 studies combined. Consequently, regular monitoring for the occurrence of
mania/hypomania is recommended.
As with other SSRIs, decreased weight gain has been observed in association with the use of fluoxetine in children and
adolescent patients. After 19 weeks of treatment in a clinical trial, pediatric subjects treated with fluoxetine gained an average of
1.1 cm less in height and 1.1 kg less in weight than subjects treated with placebo. In addition, fluoxetine treatment was associated with
a decrease in alkaline phosphatase levels. The safety of fluoxetine treatment for pediatric patients has not been systematically assessed
for chronic treatment longer than several months in duration. In particular, there are no studies that directly evaluate the longer-term
effects of fluoxetine on the growth, development and maturation of children and adolescent patients. Therefore, height and weight
should be monitored periodically in pediatric patients receiving fluoxetine. [see Warnings and Precautions (5.6)].
PROZAC is approved for use in pediatric patients with MDD and OCD [see Box Warning and Warnings and Precautions
(5.1)]. Anyone considering the use of PROZAC in a child or adolescent must balance the potential risks with the clinical need.
Significant toxicity, including myotoxicity, long-term neurobehavioral and reproductive toxicity, and impaired bone
development, has been observed following exposure of juvenile animals to fluoxetine. Some of these effects occurred at clinically
relevant exposures.
In a study in which fluoxetine (3, 10, or 30 mg/kg) was orally administered to young rats from weaning (Postnatal Day 21)
through adulthood (Day 90), male and female sexual development was delayed at all doses, and growth (body weight gain, femur
length) was decreased during the dosing period in animals receiving the highest dose. At the end of the treatment period, serum levels
of creatine kinase (marker of muscle damage) were increased at the intermediate and high doses, and abnormal muscle and
reproductive organ histopathology (skeletal muscle degeneration and necrosis, testicular degeneration and necrosis, epididymal
vacuolation and hypospermia) was observed at the high dose. When animals were evaluated after a recovery period (up to 11 weeks
after cessation of dosing), neurobehavioral abnormalities (decreased reactivity at all doses and learning deficit at the high dose) and
reproductive functional impairment (decreased mating at all doses and impaired fertility at the high dose) were seen; in addition,
testicular and epididymal microscopic lesions and decreased sperm concentrations were found in the high dose group, indicating that
the reproductive organ effects seen at the end of treatment were irreversible. The reversibility of fluoxetine-induced muscle damage
was not assessed. Adverse effects similar to those observed in rats treated with fluoxetine during the juvenile period have not been
reported after administration of fluoxetine to adult animals. Plasma exposures (AUC) to fluoxetine in juvenile rats receiving the low,
intermediate, and high dose in this study were approximately 0.1-0.2, 1-2, and 5-10 times, respectively, the average exposure in
pediatric patients receiving the maximum recommended dose (MRD) of 20 mg/day. Rat exposures to the major metabolite,
norfluoxetine, were approximately 0.3-0.8, 1-8, and 3-20 times, respectively, pediatric exposure at the MRD.
A specific effect of fluoxetine on bone development has been reported in mice treated with fluoxetine during the juvenile
period. When mice were treated with fluoxetine (5 or 20 mg/kg, intraperitoneal) for 4 weeks starting at 4 weeks of age, bone
formation was reduced resulting in decreased bone mineral content and density. These doses did not affect overall growth (body
weight gain or femoral length). The doses administered to juvenile mice in this study are approximately 0.5 and 2 times the MRD for
pediatric patients on a body surface area (mg/m2) basis.
In another mouse study, administration of fluoxetine (10 mg/kg intraperitoneal) during early postnatal development (Postnatal
Days 4 to 21) produced abnormal emotional behaviors (decreased exploratory behavior in elevated plus-maze, increase shock
avoidance latency) in adulthood (12 weeks of age). The dose used in this study is approximately equal to the pediatric MRD on a
mg/m2 basis. Because of the early dosing period in this study, the significance of these findings to the approved pediatric use in
humans is uncertain.
Safety and effectiveness of PROZAC and olanzapine in combination in patients less than 18 years of age have not been
established.

18
8.5 Geriatric Use

US fluoxetine clinical trials included 687 patients ≥65 years of age and 93 patients ≥75 years of age. The efficacy in geriatric
patients has been established [see Clinical Studies (14.1)]. For pharmacokinetic information in geriatric patients, [see Clinical
Pharmacology (12.4)]. No overall differences in safety or effectiveness were observed between these subjects and younger subjects,
and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater
sensitivity of some older individuals cannot be ruled out. SNRIs and SSRIs, including fluoxetine, have been associated with cases of
clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse reaction [see Warnings and
Precautions (5.8)].
Clinical studies of olanzapine and fluoxetine in combination did not include sufficient numbers of patients ≥65 years of age to
determine whether they respond differently from younger patients.
8.6 Hepatic Impairment
In subjects with cirrhosis of the liver, the clearances of fluoxetine and its active metabolite, norfluoxetine, were decreased,
thus increasing the elimination half-lives of these substances. A lower or less frequent dose of fluoxetine should be used in patients
with cirrhosis. Caution is advised when using PROZAC in patients with diseases or conditions that could affect its metabolism [see
Dosage and Administration (2.7) and Clinical Pharmacology (12.4)].
9 DRUG ABUSE AND DEPENDENCE
9.3 Dependence
PROZAC has not been systematically studied, in animals or humans, for its potential for abuse, tolerance, or physical
dependence. While the premarketing clinical experience with PROZAC did not reveal any tendency for a withdrawal syndrome or any
drug seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience
the extent to which a CNS active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should
carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of
PROZAC (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).
10 OVERDOSAGE
10.1 Human Experience
Worldwide exposure to fluoxetine hydrochloride is estimated to be over 38 million patients (circa 1999). Of the 1578 cases of
overdose involving fluoxetine hydrochloride, alone or with other drugs, reported from this population, there were 195 deaths.
Among 633 adult patients who overdosed on fluoxetine hydrochloride alone, 34 resulted in a fatal outcome, 378 completely
recovered, and 15 patients experienced sequelae after overdosage, including abnormal accommodation, abnormal gait, confusion,
unresponsiveness, nervousness, pulmonary dysfunction, vertigo, tremor, elevated blood pressure, impotence, movement disorder, and
hypomania. The remaining 206 patients had an unknown outcome. The most common signs and symptoms associated with non-fatal
overdosage were seizures, somnolence, nausea, tachycardia, and vomiting. The largest known ingestion of fluoxetine hydrochloride in
adult patients was 8 grams in a patient who took fluoxetine alone and who subsequently recovered. However, in an adult patient who
took fluoxetine alone, an ingestion as low as 520 mg has been associated with lethal outcome, but causality has not been established.
Among pediatric patients (ages 3 months to 17 years), there were 156 cases of overdose involving fluoxetine alone or in
combination with other drugs. Six patients died, 127 patients completely recovered, 1 patient experienced renal failure, and 22 patients
had an unknown outcome. One of the six fatalities was a 9-year-old boy who had a history of OCD, Tourette’s syndrome with tics,
attention deficit disorder, and fetal alcohol syndrome. He had been receiving 100 mg of fluoxetine daily for 6 months in addition to
clonidine, methylphenidate, and promethazine. Mixed-drug ingestion or other methods of suicide complicated all 6 overdoses in
children that resulted in fatalities. The largest ingestion in pediatric patients was 3 grams which was nonlethal.
Other important adverse reactions reported with fluoxetine overdose (single or multiple drugs) include coma, delirium,
ECG abnormalities (such as QT interval prolongation and ventricular tachycardia, including torsades de pointes-type arrhythmias),
hypotension, mania, neuroleptic malignant syndrome-like reactions, pyrexia, stupor, and syncope.
10.2 Animal Experience
Studies in animals do not provide precise or necessarily valid information about the treatment of human overdose. However,
animal experiments can provide useful insights into possible treatment strategies.
The oral median lethal dose in rats and mice was found to be 452 and 248 mg/kg, respectively. Acute high oral doses
produced hyperirritability and convulsions in several animal species.
Among 6 dogs purposely overdosed with oral fluoxetine, 5 experienced grand mal seizures. Seizures stopped immediately
upon the bolus intravenous administration of a standard veterinary dose of diazepam. In this short-term study, the lowest plasma
concentration at which a seizure occurred was only twice the maximum plasma concentration seen in humans taking 80 mg/day,
chronically.
In a separate single-dose study, the ECG of dogs given high doses did not reveal prolongation of the PR, QRS, or
QT intervals. Tachycardia and an increase in blood pressure were observed. Consequently, the value of the ECG in predicting cardiac
toxicity is unknown. Nonetheless, the ECG should ordinarily be monitored in cases of human overdose [see Overdosage (10.3)].
10.3 Management of Overdose

19
Treatment should consist of those general measures employed in the management of overdosage with any drug effective in the
treatment of Major Depressive Disorder.
Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and
symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric
tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients.
Activated charcoal should be administered. Due to the large volume of distribution of this drug, forced diuresis, dialysis,
hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for fluoxetine are known.
A specific caution involves patients who are taking or have recently taken fluoxetine and might ingest excessive quantities of
a TCA. In such a case, accumulation of the parent tricyclic and/or an active metabolite may increase the possibility of clinically
significant sequelae and extend the time needed for close medical observation [see Drug Interactions (7. 9)].
Based on experience in animals, which may not be relevant to humans, fluoxetine-induced seizures that fail to remit
spontaneously may respond to diazepam.
In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting a
poison control center for additional information on the treatment of any overdose. Telephone numbers for certified poison control
centers are listed in the Physicians’ Desk Reference (PDR).
For specific information about overdosage with olanzapine and fluoxetine in combination, refer to the Overdosage section of
the Symbyax package insert.
11 DESCRIPTION
PROZAC® (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration. It is also marketed for
the treatment of premenstrual dysphoric disorder (Sarafem®, fluoxetine hydrochloride). It is designated (±)-N-methyl-3-phenyl-3
[(α,α,α-trifluoro-p-tolyl)oxy]propylamine hydrochloride and has the empirical formula of C17H18F3NO•HCl. Its molecular weight
is 345.79. The structural formula is:
F3C O CHCH2CH2NHCH3 • HCl
Fluoxetine hydrochloride is a white to off-white crystalline solid with a solubility of 14 mg/mL in water.
Each Pulvule® contains fluoxetine hydrochloride equivalent to 10 mg (32.3 µmol), 20 mg (64.7 µmol), or 40 mg (129.3 µmol)
of fluoxetine. The Pulvules also contain starch, gelatin, silicone, titanium dioxide, iron oxide, and other inactive ingredients. The 10
and 20 mg Pulvules also contain FD&C Blue No. 1, and the 40 mg Pulvule also contains FD&C Blue No. 1 and FD&C Yellow No. 6.
PROZAC Weekly™ capsules, a delayed-release formulation, contain enteric-coated pellets of fluoxetine hydrochloride
equivalent to 90 mg (291 µmol) of fluoxetine. The capsules also contain D&C Yellow No. 10, FD&C Blue No. 2, gelatin,
hypromellose, hypromellose acetate succinate, sodium lauryl sulfate, sucrose, sugar spheres, talc, titanium dioxide, triethyl citrate, and
other inactive ingredients.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Although the exact mechanism of PROZAC is unknown, it is presumed to be linked to its inhibition of CNS neuronal uptake
of serotonin.
12.2 Pharmacodynamics
Studies at clinically relevant doses in man have demonstrated that fluoxetine blocks the uptake of serotonin into human
platelets. Studies in animals also suggest that fluoxetine is a much more potent uptake inhibitor of serotonin than of norepinephrine.
Antagonism of muscarinic, histaminergic, and α1-adrenergic receptors has been hypothesized to be associated with various
anticholinergic, sedative, and cardiovascular effects of classical tricyclic antidepressant (TCA) drugs. Fluoxetine binds to these and
other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs.
12.3 Pharmacokinetics
Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to
55 ng/mL are observed after 6 to 8 hours.
The Pulvule and PROZAC Weekly capsule dosage forms of fluoxetine are bioequivalent. Food does not appear to affect the
systemic bioavailability of fluoxetine, although it may delay its absorption by 1 to 2 hours, which is probably not clinically significant.
Thus, fluoxetine may be administered with or without food. PROZAC Weekly capsules, a delayed-release formulation, contain
enteric-coated pellets that resist dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5. The enteric
coating delays the onset of absorption of fluoxetine 1 to 2 hours relative to the immediate-release formulations.

20
Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound
in vitro to human serum proteins, including albumin and α1-glycoprotein. The interaction between fluoxetine and other highly
protein-bound drugs has not been fully evaluated, but may be important.
Enantiomers — Fluoxetine is a racemic mixture (50/50) of R-fluoxetine and S-fluoxetine enantiomers. In animal models, both
enantiomers are specific and potent serotonin uptake inhibitors with essentially equivalent pharmacologic activity. The S-fluoxetine
enantiomer is eliminated more slowly and is the predominant enantiomer present in plasma at steady state.
Metabolism — Fluoxetine is extensively metabolized in the liver to norfluoxetine and a number of other unidentified
metabolites. The only identified active metabolite, norfluoxetine, is formed by demethylation of fluoxetine. In animal models,
S-norfluoxetine is a potent and selective inhibitor of serotonin uptake and has activity essentially equivalent to R- or S-fluoxetine.
R-norfluoxetine is significantly less potent than the parent drug in the inhibition of serotonin uptake. The primary route of elimination
appears to be hepatic metabolism to inactive metabolites excreted by the kidney.
Variability in Metabolism — A subset (about 7%) of the population has reduced activity of the drug metabolizing enzyme
cytochrome P450 2D6 (CYP2D6). Such individuals are referred to as “poor metabolizers” of drugs such as debrisoquin,
dextromethorphan, and the TCAs. In a study involving labeled and unlabeled enantiomers administered as a racemate, these
individuals metabolized S-fluoxetine at a slower rate and thus achieved higher concentrations of S-fluoxetine. Consequently,
concentrations of S-norfluoxetine at steady state were lower. The metabolism of R-fluoxetine in these poor metabolizers appears
normal. When compared with normal metabolizers, the total sum at steady state of the plasma concentrations of the 4 active
enantiomers was not significantly greater among poor metabolizers. Thus, the net pharmacodynamic activities were essentially the
same. Alternative, nonsaturable pathways (non-2D6) also contribute to the metabolism of fluoxetine. This explains how fluoxetine
achieves a steady-state concentration rather than increasing without limit.
Because fluoxetine’s metabolism, like that of a number of other compounds including TCAs and other selective serotonin
reuptake inhibitors (SSRIs), involves the CYP2D6 system, concomitant therapy with drugs also metabolized by this enzyme system
(such as the TCAs) may lead to drug interactions [see Drug Interactions (7.9)].
Accumulation and Slow Elimination — The relatively slow elimination of fluoxetine (elimination half-life of 1 to 3 days after
acute administration and 4 to 6 days after chronic administration) and its active metabolite, norfluoxetine (elimination half-life of 4 to
16 days after acute and chronic administration), leads to significant accumulation of these active species in chronic use and delayed
attainment of steady state, even when a fixed dose is used [see Warnings and Precautions (5.12)]. After 30 days of dosing at
40 mg/day, plasma concentrations of fluoxetine in the range of 91 to 302 ng/mL and norfluoxetine in the range of 72 to 258 ng/mL
have been observed. Plasma concentrations of fluoxetine were higher than those predicted by single-dose studies, because fluoxetine’s
metabolism is not proportional to dose. Norfluoxetine, however, appears to have linear pharmacokinetics. Its mean terminal half-life
after a single dose was 8.6 days and after multiple dosing was 9.3 days. Steady-state levels after prolonged dosing are similar to levels
seen at 4 to 5 weeks.
The long elimination half-lives of fluoxetine and norfluoxetine assure that, even when dosing is stopped, active drug substance
will persist in the body for weeks (primarily depending on individual patient characteristics, previous dosing regimen, and length of
previous therapy at discontinuation). This is of potential consequence when drug discontinuation is required or when drugs are
prescribed that might interact with fluoxetine and norfluoxetine following the discontinuation of PROZAC.
Weekly Dosing — Administration of PROZAC Weekly once weekly results in increased fluctuation between peak and trough
concentrations of fluoxetine and norfluoxetine compared with once-daily dosing [for fluoxetine: 24% (daily) to 164% (weekly) and
for norfluoxetine: 17% (daily) to 43% (weekly)]. Plasma concentrations may not necessarily be predictive of clinical response. Peak
concentrations from once-weekly doses of PROZAC Weekly capsules of fluoxetine are in the range of the average concentration for
20 mg once-daily dosing. Average trough concentrations are 76% lower for fluoxetine and 47% lower for norfluoxetine than the
concentrations maintained by 20 mg once-daily dosing. Average steady-state concentrations of either once-daily or once-weekly
dosing are in relative proportion to the total dose administered. Average steady-state fluoxetine concentrations are approximately
50% lower following the once-weekly regimen compared with the once-daily regimen.
Cmax for fluoxetine following the 90 mg dose was approximately 1.7-fold higher than the Cmax value for the established 20 mg
once-daily regimen following transition the next day to the once-weekly regimen. In contrast, when the first 90 mg once-weekly dose
and the last 20 mg once-daily dose were separated by 1 week, Cmax values were similar. Also, there was a transient increase in the
average steady-state concentrations of fluoxetine observed following transition the next day to the once-weekly regimen. From a
pharmacokinetic perspective, it may be better to separate the first 90 mg weekly dose and the last 20 mg once-daily dose by 1 week
[see Dosage and Administration (2.1)].
12.4 Specific Populations
Liver Disease — As might be predicted from its primary site of metabolism, liver impairment can affect the elimination of
fluoxetine. The elimination half-life of fluoxetine was prolonged in a study of cirrhotic patients, with a mean of 7.6 days compared
with the range of 2 to 3 days seen in subjects without liver disease; norfluoxetine elimination was also delayed, with a mean duration
of 12 days for cirrhotic patients compared with the range of 7 to 9 days in normal subjects. This suggests that the use of fluoxetine in
patients with liver disease must be approached with caution. If fluoxetine is administered to patients with liver disease, a lower or less
frequent dose should be used [see Dosage and Administration (2.7), Use in Specific Populations (8.6)].

21
Renal Disease — In depressed patients on dialysis (N=12), fluoxetine administered as 20 mg once daily for 2 months
produced steady-state fluoxetine and norfluoxetine plasma concentrations comparable with those seen in patients with normal renal
function. While the possibility exists that renally excreted metabolites of fluoxetine may accumulate to higher levels in patients with
severe renal dysfunction, use of a lower or less frequent dose is not routinely necessary in renally impaired patients.
Geriatric Pharmacokinetics — The disposition of single doses of fluoxetine in healthy elderly subjects (>65 years of age) did
not differ significantly from that in younger normal subjects. However, given the long half-life and nonlinear disposition of the drug, a
single-dose study is not adequate to rule out the possibility of altered pharmacokinetics in the elderly, particularly if they have
systemic illness or are receiving multiple drugs for concomitant diseases. The effects of age upon the metabolism of fluoxetine have
been investigated in 260 elderly but otherwise healthy depressed patients (≥60 years of age) who received 20 mg fluoxetine for
6 weeks. Combined fluoxetine plus norfluoxetine plasma concentrations were 209.3 ± 85.7 ng/mL at the end of 6 weeks. No unusual
age-associated pattern of adverse reactions was observed in those elderly patients.
Pediatric Pharmacokinetics (children and adolescents) — Fluoxetine pharmacokinetics were evaluated in 21 pediatric
patients (10 children ages 6 to <13, 11 adolescents ages 13 to <18) diagnosed with Major Depressive Disorder or Obsessive
Compulsive Disorder (OCD). Fluoxetine 20 mg/day was administered for up to 62 days. The average steady-state concentrations of
fluoxetine in these children were 2-fold higher than in adolescents (171 and 86 ng/mL, respectively). The average norfluoxetine
steady-state concentrations in these children were 1.5-fold higher than in adolescents (195 and 113 ng/mL, respectively). These
differences can be almost entirely explained by differences in weight. No gender-associated difference in fluoxetine pharmacokinetics
was observed. Similar ranges of fluoxetine and norfluoxetine plasma concentrations were observed in another study in 94 pediatric
patients (ages 8 to <18) diagnosed with Major Depressive Disorder.
Higher average steady-state fluoxetine and norfluoxetine concentrations were observed in children relative to adults; however,
these concentrations were within the range of concentrations observed in the adult population. As in adults, fluoxetine and
norfluoxetine accumulated extensively following multiple oral dosing; steady-state concentrations were achieved within 3 to 4 weeks
of daily dosing.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity — The dietary administration of fluoxetine to rats and mice for 2 years at doses of up to 10 and
12 mg/kg/day, respectively [approximately 1.2 and 0.7 times, respectively, the maximum recommended human dose (MRHD) of
80 mg on a mg/m2 basis], produced no evidence of carcinogenicity.
Mutagenicity — Fluoxetine and norfluoxetine have been shown to have no genotoxic effects based on the following
assays: bacterial mutation assay, DNA repair assay in cultured rat hepatocytes, mouse lymphoma assay, and in vivo sister chromatid
exchange assay in Chinese hamster bone marrow cells.
Impairment of Fertility — Two fertility studies conducted in adult rats at doses of up to 7.5 and 12.5 mg/kg/day
(approximately 0.9 and 1.5 times the MRHD on a mg/m2 basis) indicated that fluoxetine had no adverse effects on fertility. However,
adverse effects on fertility were seen when juvenile rats were treated with fluoxetine [see Use in Specific Populations (8.4)].
13.2 Animal Toxicology and/or Pharmacology
Phospholipids are increased in some tissues of mice, rats, and dogs given fluoxetine chronically. This effect is reversible after
cessation of fluoxetine treatment. Phospholipid accumulation in animals has been observed with many cationic amphiphilic drugs,
including fenfluramine, imipramine, and ranitidine. The significance of this effect in humans is unknown.
14 CLINICAL STUDIES
Symbyax.
Daily Dosing
Adult — The efficacy of PROZAC was studied in 5- and 6-week placebo-controlled trials with depressed adult and geriatric
outpatients (≥18 years of age) whose diagnoses corresponded most closely to the DSM-III (currently DSM-IV) category of Major
Depressive Disorder. PROZAC was shown to be significantly more effective than placebo as measured by the Hamilton Depression
Rating Scale (HAM-D). PROZAC was also significantly more effective than placebo on the HAM-D subscores for depressed mood,
sleep disturbance, and the anxiety subfactor.
Two 6-week controlled studies (N=671, randomized) comparing PROZAC 20 mg and placebo have shown PROZAC 20 mg
daily to be effective in the treatment of elderly patients (≥60 years of age) with Major Depressive Disorder. In these studies, PROZAC
produced a significantly higher rate of response and remission as defined, respectively, by a 50% decrease in the HAM-D score and a
total endpoint HAM-D score of ≤8. PROZAC was well tolerated and the rate of treatment discontinuations due to adverse reactions
did not differ between PROZAC (12%) and placebo (9%).
A study was conducted involving depressed outpatients who had responded (modified HAMD-17 score of ≤7 during each of
the last 3 weeks of open-label treatment and absence of Major Depressive Disorder by DSM-III-R criteria) by the end of an initial
12-week open-treatment phase on PROZAC 20 mg/day. These patients (N=298) were randomized to continuation on double-blind

22
PROZAC 20 mg/day or placebo. At 38 weeks (50 weeks total), a statistically significantly lower relapse rate (defined as symptoms
sufficient to meet a diagnosis of Major Depressive Disorder for 2 weeks or a modified HAMD-17 score of ≥14 for 3 weeks) was
observed for patients taking PROZAC compared with those on placebo.
Pediatric (children and adolescents) — The efficacy of PROZAC 20 mg/day in children and adolescents (N=315 randomized;
170 children ages 8 to <13, 145 adolescents ages 13 to ≤18) was studied in two 8- to 9-week placebo-controlled clinical trials in
depressed outpatients whose diagnoses corresponded most closely to the DSM-III-R or DSM-IV category of Major Depressive
Disorder.
In both studies independently, PROZAC produced a statistically significantly greater mean change on the Childhood
Depression Rating Scale-Revised (CDRS-R) total score from baseline to endpoint than did placebo.
Subgroup analyses on the CDRS-R total score did not suggest any differential responsiveness on the basis of age or gender.
Weekly dosing for Maintenance/Continuation Treatment
A longer-term study was conducted involving adult outpatients meeting DSM-IV criteria for Major Depressive Disorder who
had responded (defined as having a modified HAMD-17 score of ≤9, a CGI-Severity rating of ≤2, and no longer meeting criteria for
Major Depressive Disorder) for 3 consecutive weeks at the end of 13 weeks of open-label treatment with PROZAC 20 mg once daily.
These patients were randomized to double-blind, once-weekly continuation treatment with PROZAC Weekly, PROZAC 20 mg once
daily, or placebo. PROZAC Weekly once weekly and PROZAC 20 mg once daily demonstrated superior efficacy (having a
significantly longer time to relapse of depressive symptoms) compared with placebo for a period of 25 weeks. However, the
equivalence of these 2 treatments during continuation therapy has not been established.
Adult — The effectiveness of PROZAC for the treatment of Obsessive Compulsive Disorder (OCD) was demonstrated in
two 13-week, multicenter, parallel group studies (Studies 1 and 2) of adult outpatients who received fixed PROZAC doses of 20, 40,
or 60 mg/day (on a once-a-day schedule, in the morning) or placebo. Patients in both studies had moderate to severe
OCD (DSM-III-R), with mean baseline ratings on the Yale-Brown Obsessive Compulsive Scale (YBOCS, total score) ranging from
22 to 26. In Study 1, patients receiving PROZAC experienced mean reductions of approximately 4 to 6 units on the YBOCS total
score, compared with a 1-unit reduction for placebo patients. In Study 2, patients receiving PROZAC experienced mean reductions of
approximately 4 to 9 units on the YBOCS total score, compared with a 1-unit reduction for placebo patients. While there was no
indication of a dose-response relationship for effectiveness in Study 1, a dose-response relationship was observed in Study 2, with
numerically better responses in the 2 higher dose groups. The following table provides the outcome classification by treatment group
on the Clinical Global Impression (CGI) improvement scale for Studies 1 and 2 combined:
Table 6
Outcome Classification (%) on CGI Improvement Scale for
Completers in Pool of Two OCD Studies
PROZAC
Outcome Classification Placebo 20 mg 40 mg 60 mg
Worse 8% 0% 0% 0%
No change 64% 41% 33% 29%
Minimally improved 17% 23% 28% 24%
Much improved 8% 28% 27% 28%
Very much improved 3% 8% 12% 19%
Exploratory analyses for age and gender effects on outcome did not suggest any differential responsiveness on the basis of age
or sex.
Pediatric (children and adolescents) — In one 13-week clinical trial in pediatric patients (N=103 randomized; 75 children
ages 7 to <13, 28 adolescents ages 13 to <18) with OCD (DSM-IV), patients received PROZAC 10 mg/day for 2 weeks, followed by
20 mg/day for 2 weeks. The dose was then adjusted in the range of 20 to 60 mg/day on the basis of clinical response and tolerability.
PROZAC produced a statistically significantly greater mean change from baseline to endpoint than did placebo as measured by the
Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS).
Subgroup analyses on outcome did not suggest any differential responsiveness on the basis of age or gender.
14.3 Bulimia Nervosa
The effectiveness of PROZAC for the treatment of bulimia was demonstrated in two 8-week and one 16-week, multicenter,
parallel group studies of adult outpatients meeting DSM-III-R criteria for bulimia. Patients in the 8-week studies received either 20 or
60 mg/day of PROZAC or placebo in the morning. Patients in the 16-week study received a fixed PROZAC dose of 60 mg/day (once
a day) or placebo. Patients in these 3 studies had moderate to severe bulimia with median binge-eating and vomiting frequencies
ranging from 7 to 10 per week and 5 to 9 per week, respectively. In these 3 studies, PROZAC 60 mg, but not 20 mg, was statistically
significantly superior to placebo in reducing the number of binge-eating and vomiting episodes per week. The statistically
significantly superior effect of 60 mg versus placebo was present as early as Week 1 and persisted throughout each study. The

23
PROZAC-related reduction in bulimic episodes appeared to be independent of baseline depression as assessed by the Hamilton
Depression Rating Scale. In each of these 3 studies, the treatment effect, as measured by differences between PROZAC 60 mg and
placebo on median reduction from baseline in frequency of bulimic behaviors at endpoint, ranged from 1 to 2 episodes per week for
binge-eating and 2 to 4 episodes per week for vomiting. The size of the effect was related to baseline frequency, with greater
reductions seen in patients with higher baseline frequencies. Although some patients achieved freedom from binge-eating and purging
as a result of treatment, for the majority, the benefit was a partial reduction in the frequency of binge-eating and purging.
In a longer-term trial, 150 patients meeting DSM-IV criteria for Bulimia Nervosa, purging subtype, who had responded during
a single-blind, 8-week acute treatment phase with PROZAC 60 mg/day, were randomized to continuation of PROZAC 60 mg/day or
placebo, for up to 52 weeks of observation for relapse. Response during the single-blind phase was defined by having achieved at least
a 50% decrease in vomiting frequency compared with baseline. Relapse during the double-blind phase was defined as a persistent
return to baseline vomiting frequency or physician judgment that the patient had relapsed. Patients receiving continued
PROZAC 60 mg/day experienced a significantly longer time to relapse over the subsequent 52 weeks compared with those receiving
placebo.
14.4 Panic Disorder
The effectiveness of PROZAC in the treatment of Panic Disorder was demonstrated in 2 double-blind, randomized,
placebo-controlled, multicenter studies of adult outpatients who had a primary diagnosis of Panic Disorder (DSM-IV), with or without
agoraphobia.
Study 1 (N=180 randomized) was a 12-week flexible-dose study. PROZAC was initiated at 10 mg/day for the first week, after
which patients were dosed in the range of 20 to 60 mg/day on the basis of clinical response and tolerability. A statistically
significantly greater percentage of PROZAC-treated patients were free from panic attacks at endpoint than placebo-treated patients,
42% versus 28%, respectively.
Study 2 (N=214 randomized) was a 12-week flexible-dose study. PROZAC was initiated at 10 mg/day for the first week, after
which patients were dosed in a range of 20 to 60 mg/day on the basis of clinical response and tolerability. A statistically significantly
greater percentage of PROZAC-treated patients were free from panic attacks at endpoint than placebo-treated patients,
62% versus 44%, respectively.
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
The following products are manufactured by Eli Lilly and Company for Dista Products Company:
Pulvule are available in 10mg, 20mg and 40mg capsule strengths and packages as follows:
Pulvule Strength
10 mg1 20 mg1 40 mg1
2
Pulvule No. PU3104 PU3105 PU3107
Cap Color Opaque green Opaque green Opaque green
Body Color Opaque green Opaque yellow Opaque orange
Identification DISTA 3104 DISTA 3105 DISTA 3107
Prozac 10 mg Prozac 20 mg Prozac 40 mg
NDC Codes:
Bottles of 30 0777-3105-30 0777-3107-30
Bottles 100 0777-3104-02 0777-3105-02
Bottles of 2000 0777-3105-07
The following product is manufactured and distributed by Eli Lilly and Company:
PROZAC® Weekly™ Capsules are available in:
The 90 mg1 capsule is an opaque green cap and clear body containing discretely visible white pellets through the clear body of
the capsule, imprinted with Lilly on the cap and 3004 and 90 mg on the body.
NDC 0002-3004-75 (PU3004) – Blister package of 4

______________________
1
Fluoxetine base equivalent.
2
Protect from light.
16.2 Storage and Handling

24
Store at Controlled Room Temperature, 15° to 30°C (59° to 86°F).

17 PATIENT COUNSELING INFORMATION
See the FDA-approved Medication Guide.
Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking PROZAC as
monotherapy or in combination with olanzapine. When using PROZAC and olanzapine in combination, also refer to the Patient
Counseling Information section of the package insert for Symbyax.
17.1 General Information
Healthcare providers should instruct their patients to read the Medication Guide before starting therapy with PROZAC and to
reread it each time the prescription is renewed.
Healthcare providers should inform patients, their families, and their caregivers about the benefits and risks associated with
treatment with PROZAC and should counsel them in its appropriate use. Healthcare providers should instruct patients, their families,
and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the
opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have.
Patients should be advised of the following issues and asked to alert their healthcare provider if these occur while taking
PROZAC.
When using PROZAC and olanzapine in combination, also refer to the Medication Guide for Symbyax.
17.2 Clinical Worsening and Suicide Risk
Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic
attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other
unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and
when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such
symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient’s prescriber or health
professional, especially if they are severe, abrupt in onset, or were not part of the patient’s presenting symptoms. Symptoms such as
these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and
possibly changes in the medication [see Box Warning and Warnings and Precautions (5.1)].
17.3 Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions
Patients should be cautioned about the risk of serotonin syndrome or NMS-like reactions with the concomitant use of
PROZAC and triptans, tramadol, or other serotonergic agents [see Warnings and Precautions (5.2) and Drug Interactions (7.3)].
Patients should be advised of the signs and symptoms associated with serotonin syndrome or NMS-like reactions that may
include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure,
hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea,
vomiting, diarrhea). Serotonin syndrome, in its most severe form can resemble neuroleptic malignant syndrome, in which the
symptoms may include hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental
status changes. Patients should be cautioned to seek medical care immediately if they experience these symptoms.
Patients should be advised to notify their physician if they develop a rash or hives [see Warnings and Precautions (5.3)].
Patients should also be advised of the signs and symptoms associated with a severe allergic reaction, including swelling of the face,
eyes, or mouth, or have trouble breathing. Patients should be cautioned to seek medical care immediately if they experience these
symptoms.
17.5 Abnormal Bleeding
Patients should be cautioned about the concomitant use of fluoxetine and NSAIDs, aspirin, warfarin, or other drugs that affect
coagulation since combined use of psychotropic drugs that interfere with serotonin reuptake and these agents have been associated
with an increased risk of bleeding [see Warnings and Precautions (5.7) and Drug Interactions (7.6)]. Patients should be advised to
call their doctor if they experience any increased or unusual bruising or bleeding while taking PROZAC.
17.6 Hyponatremia
Patients should be advised that hyponatremia has been reported as a result of treatment with SNRIs and SSRIs, including
PROZAC. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion,
weakness, and unsteadiness, which may lead to falls. More severe and/or acute cases have been associated with hallucination,
syncope, seizure, coma, respiratory arrest, and death [see Warnings and Precautions (5.8)].
17.7 Potential for Cognitive and Motor Impairment
PROZAC may impair judgment, thinking, or motor skills. Patients should be advised to avoid driving a car or operating
hazardous machinery until they are reasonably certain that their performance is not affected [see Warnings and Precautions (5.11)].
17.8 Use of Concomitant Medications

25
Patients should be advised to inform their physician if they are taking, or plan to take, any prescription medication, including
Symbyax, Sarafem, or over-the-counter drugs, including herbal supplements or alcohol. Patients should also be advised to inform their
physicians if they plan to discontinue any medications they are taking while on PROZAC.
Patients should be advised to take PROZAC exactly as prescribed, and to continue taking PROZAC as prescribed even after
their symptoms improve. Patients should be advised that they should not alter their dosing regimen, or stop taking PROZAC without
consulting their physician [see Warnings and Precautions (5.13)]. Patients should be advised to consult with their healthcare provider
if their symptoms do not improve with PROZAC.
17.10 Use in Specific Populations
Pregnancy — Patients should be advised to notify their physician if they become pregnant or intend to become pregnant
during therapy. Prozac should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus [see Use in
Specific Populations (8.1)].
Nursing Mothers — Patients should be advised to notify their physician if they intend to breast-feed an infant during therapy.
Because PROZAC is excreted in human milk, nursing while taking PROZAC is not recommended [see Use in Specific Populations
(8.3)].
Pediatric Use — PROZAC is approved for use in pediatric patients with MDD and OCD [see Box Warning and Warnings
and Precautions (5.1)]. Limited evidence is available concerning the longer-term effects of fluoxetine on the development and
maturation of children and adolescent patients. Height and weight should be monitored periodically in pediatric patients receiving
fluoxetine. Safety and effectiveness of PROZAC and olanzapine in combination in patients less than 18 years of age have not been
established [see Warnings and Precautions (5.6) and Use in Specific Populations (8.4)].
Literature revised Month dd, yyyy

Eli Lilly and Company, Indianapolis, IN 46285, USA
Copyright © 1987, XXXX, Eli Lilly and Company. All rights reserved.
A4.0 NL 7430 DPP

See Full Prescribing Information For Complete Boxed Warning

Uploaded by

Copyright:

Available Formats

See Full Prescribing Information For Complete Boxed Warning

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

See Full Prescribing Information For Complete Boxed Warning

Uploaded by

Copyright:

Available Formats

1

Reference ID: 2927282

5.3 Allergic Reactions and Rash 14.1 Major Depressive Disorder

Mania/Hypomania 14.3 Bulimia Nervosa

5.5 Seizures 14.4 Panic Disorder

Reference ID: 2927282

FULL PRESCRIBING INFORMATION

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

1 INDICATIONS AND USAGE

Reference ID: 2927282

Reference ID: 2927282

Reference ID: 2927282

Reference ID: 2927282

Table 2: Suicidality per 1000 Patients Treated

Reference ID: 2927282

Reference ID: 2927282

Reference ID: 2927282

Reference ID: 2927282

Disorder Placebo-Controlled Clinical Trials1,2

Percentage of Patients Reporting Event

Reference ID: 2927282

and Panic Disorder Combined

Reference ID: 2927282

Anxiety (1%) -- Anxiety (2%) -- Anxiety (2%)

Reference ID: 2927282

Reference ID: 2927282

Reference ID: 2927282

Reference ID: 2927282

Reference ID: 2927282

8.5 Geriatric Use

Reference ID: 2927282

F3C O CHCH2CH2NHCH3 • HCl

Reference ID: 2927282

Reference ID: 2927282

Reference ID: 2927282

Reference ID: 2927282

PROZAC® Weekly™ Capsules are available in:

NDC 0002-3004-75 (PU3004) – Blister package of 4

16.2 Storage and Handling

Reference ID: 2927282

Store at Controlled Room Temperature, 15° to 30°C (59° to 86°F).

Reference ID: 2927282

Literature revised Month dd, yyyy

Reference ID: 2927282

You might also like